US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US7041871B1
(en)
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
*
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US7084260B1
(en)
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5795966A
(en)
†
|
1995-02-22 |
1998-08-18 |
Immunex Corp |
Antagonists of interleukin-15
|
ATE390933T1
(de)
*
|
1995-04-27 |
2008-04-15 |
Amgen Fremont Inc |
Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
|
US7429646B1
(en)
|
1995-06-05 |
2008-09-30 |
Human Genome Sciences, Inc. |
Antibodies to human tumor necrosis factor receptor-like 2
|
EP0823941A4
(de)
*
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
Menschliche antikörper aus xenomäusen
|
US6632976B1
(en)
|
1995-08-29 |
2003-10-14 |
Kirin Beer Kabushiki Kaisha |
Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US7964190B2
(en)
|
1996-03-22 |
2011-06-21 |
Human Genome Sciences, Inc. |
Methods and compositions for decreasing T-cell activity
|
US6635743B1
(en)
|
1996-03-22 |
2003-10-21 |
Human Genome Sciences, Inc. |
Apoptosis inducing molecule II and methods of use
|
EP0966971A1
(de)
|
1996-04-23 |
1999-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Präventivum oder wirkstoff gegen hirnschlag/cerebrales ödem, mit il-8 inhibitor als aktivem inhaltsstoff
|
EP0962467A4
(de)
|
1996-09-26 |
2002-10-30 |
Chugai Pharmaceutical Co Ltd |
Antikörper gegen menschliches parathormon verwandten peptide
|
AU2450102A
(en)
*
|
1996-12-03 |
2002-08-08 |
Abgenix, Inc. |
Transgenic mammals having human IG LOCI including plural Vh and Vk regions and antibodies produced therefrom
|
PT942968E
(pt)
*
|
1996-12-03 |
2008-03-27 |
Amgen Fremont Inc |
Anticorpos totalmente humanos que se ligam ao egfr
|
DK2011514T3
(da)
|
1997-03-21 |
2012-03-26 |
Chugai Pharmaceutical Co Ltd |
Forebyggende eller terapeutisk middel til sensibiliserede-T-celle-medierede sygdomme omfattende IL-6-antagonist som en aktiv bestanddel
|
US6235883B1
(en)
*
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
UA74130C2
(uk)
|
1997-05-15 |
2005-11-15 |
Чугаі Сейяку Кабусікі Кайся |
ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ БІЛКА, СПОРІДНЕНОГО З ПАРАТИРЕОЇДНИМ ГОРМОНОМ (PTHrP), АБО ЙОГО ФУНКЦІОНАЛЬНО АКТИВНОГО ФРАГМЕНТА І/АБО ЙОГО МОДИФІКОВАНОГО ФРАГМЕНТА ДЛЯ ВИРОБНИЦТВА ЛІКАРСЬКОГО ЗАСОБУ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ КАХЕКСІЇ
|
EP1004315B1
(de)
|
1997-08-15 |
2008-05-21 |
Chugai Seiyaku Kabushiki Kaisha |
Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
|
WO2000017353A1
(en)
*
|
1998-09-22 |
2000-03-30 |
Genentech, Inc. |
Ucp4
|
WO1999027105A2
(en)
|
1997-11-21 |
1999-06-03 |
Genset |
Chlamydia pneumoniae genomic sequence and polypeptides, fragments thereof and uses thereof, in particular for the diagnosis, prevention and treatment of infection
|
EP2218730A1
(de)
|
1997-11-28 |
2010-08-18 |
Merck Serono Biodevelopment |
Genomsequenz von Chlamydia trachomatis sowie Polypeptide, Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
|
WO1999047170A1
(fr)
|
1998-03-17 |
1999-09-23 |
Chugai Seiyaku Kabushiki Kaisha |
Agents prophylactiques ou therapeutiques pour affections intestinales inflammatoires renfermant, comme ingredient actif, des antagonistes de il-6
|
US20020029391A1
(en)
*
|
1998-04-15 |
2002-03-07 |
Claude Geoffrey Davis |
Epitope-driven human antibody production and gene expression profiling
|
EP1895001B1
(de)
|
1998-11-04 |
2011-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Neue Serinproteasen der Trypsin-Familie
|
SI2112166T1
(sl)
*
|
1998-12-23 |
2019-05-31 |
Pfizer Inc. |
Človeška monoklonska protitelesa proti CTLA-4
|
EE05627B1
(et)
|
1998-12-23 |
2013-02-15 |
Pfizer Inc. |
CTLA-4 vastased inimese monoklonaalsed antikehad
|
US7109003B2
(en)
|
1998-12-23 |
2006-09-19 |
Abgenix, Inc. |
Methods for expressing and recovering human monoclonal antibodies to CTLA-4
|
DE60023451T2
(de)
*
|
1999-02-05 |
2006-07-20 |
Therapeutic Human Polyclonals, Inc., Mountain View |
Aus nicht-menschlichen transgenen tieren gewonnene menschliche polyklonale antikörper
|
EP1161451A4
(de)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
Menschliches alpha-endokin und verfahren zu seiner verwendung
|
US6914128B1
(en)
|
1999-03-25 |
2005-07-05 |
Abbott Gmbh & Co. Kg |
Human antibodies that bind human IL-12 and methods for producing
|
CA2796140A1
(en)
*
|
1999-03-25 |
2000-09-28 |
Jochen Salfeld |
Human antibodies that bind human il-12 and methods for producing
|
WO2000061744A1
(fr)
|
1999-04-09 |
2000-10-19 |
Chugai Research Institute For Molecular Medicine, Inc. |
Nouveaux genes de foetus
|
DE60043728D1
(de)
|
1999-06-02 |
2010-03-11 |
Chugai Pharmaceutical Co Ltd |
Neues hämopoietin rezeptorprotein nr10
|
TWI255718B
(en)
*
|
1999-07-02 |
2006-06-01 |
Chugai Pharmaceutical Co Ltd |
Ameliorative agent for low vasopressin concentration
|
AU5708500A
(en)
*
|
1999-07-02 |
2001-01-22 |
Chugai Seiyaku Kabushiki Kaisha |
Remedies for diseases caused by pth or pthrp
|
CZ20014730A3
(cs)
*
|
1999-07-06 |
2002-04-17 |
Chugai Seiyaku Kabushiki Kaisha |
Terapeutické činidlo pro hyperkalcinémii
|
TWI290832B
(en)
|
1999-08-23 |
2007-12-11 |
Chugai Pharmaceutical Co Ltd |
Expression enhancer for HM1.24 antigen
|
CA2589418A1
(en)
*
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
AU6871900A
(en)
|
1999-09-06 |
2001-04-10 |
Chugai Seiyaku Kabushiki Kaisha |
Tsg-like gene
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
EP1223217A4
(de)
|
1999-09-21 |
2003-06-25 |
Chugai Pharmaceutical Co Ltd |
Transporter-gene oatp-b, c, d und e
|
CA2388408A1
(en)
|
1999-10-01 |
2001-04-12 |
Chugai Seiyaku Kabushiki Kaisha |
Prevention and treatment of diseases associated with blood coagulation
|
US6794132B2
(en)
*
|
1999-10-02 |
2004-09-21 |
Biosite, Inc. |
Human antibodies
|
US7135287B1
(en)
|
1999-10-02 |
2006-11-14 |
Biosite, Inc. |
Human antibodies
|
US6680209B1
(en)
|
1999-12-06 |
2004-01-20 |
Biosite, Incorporated |
Human antibodies as diagnostic reagents
|
AU2228901A
(en)
*
|
1999-12-28 |
2001-07-09 |
Chugai Seiyaku Kabushiki Kaisha |
Stable antibody compositions and injection preparations
|
BR0107799A
(pt)
|
2000-01-24 |
2002-10-22 |
Haruo Sugiyama |
Proteìna de interação de wt1 wtip
|
US20030049211A1
(en)
*
|
2000-01-25 |
2003-03-13 |
Atsuhiko Kato |
Remedies and preventives for dental diseases
|
SK12942002A3
(sk)
|
2000-02-10 |
2003-05-02 |
Abbott Laboratories |
Protilátky viažuce ľudský interleukín-18, spôsoby ich výroby a použitia
|
US6653448B1
(en)
|
2000-03-29 |
2003-11-25 |
Curagen Corporation |
Wnt-7B-like polypeptides and nucleic acids encoding same
|
CA2401357A1
(en)
*
|
2000-02-28 |
2001-09-07 |
Chugai Seiyaku Kabushiki Kaisha |
Tissue degradation inhibitor agent
|
GB0006398D0
(en)
*
|
2000-03-16 |
2000-05-03 |
Novartis Ag |
Organic compounds
|
EP1832599A3
(de)
|
2000-04-12 |
2007-11-21 |
Human Genome Sciences, Inc. |
Albuminfusionsproteine
|
WO2001083755A2
(en)
*
|
2000-04-28 |
2001-11-08 |
La Jolla Institute For Allergy And Immunology |
Human anti-cd40 antibodies and methods of making and using same
|
WO2001082968A1
(fr)
|
2000-04-28 |
2001-11-08 |
Chugai Seiyaku Kabushiki Kaisha |
Inhibiteurs de proliferation cellulaire
|
US7063845B2
(en)
|
2000-04-28 |
2006-06-20 |
Gemini Science, Inc. |
Human anti-CD40 antibodies
|
ES2192426B1
(es)
*
|
2000-05-11 |
2005-02-16 |
Universidad De Vigo |
Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia.
|
ATE551363T1
(de)
*
|
2000-05-26 |
2012-04-15 |
Immunex Corp |
Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen
|
US20030031675A1
(en)
|
2000-06-06 |
2003-02-13 |
Mikesell Glen E. |
B7-related nucleic acids and polypeptides useful for immunomodulation
|
EP2431054A3
(de)
|
2000-06-15 |
2013-03-06 |
Human Genome Sciences, Inc. |
Menschlicher Tumornekrosefaktor Delta und Ypsilon
|
NZ522700A
(en)
|
2000-06-16 |
2006-02-24 |
Human Genome Sciences Inc |
Antibodies that immunospecifically bind to blys
|
EP1294879B1
(de)
|
2000-06-28 |
2008-12-31 |
Amgen Inc. |
Thymus-stroma lymphopoietin rezeptor-moleküle und deren verwendung
|
EP2386575A3
(de)
|
2000-06-29 |
2011-11-30 |
Abbott Laboratories |
Antikörper mit Doppelspezifität und Verfahren zu deren Herstellung und Benutzung
|
UA81743C2
(uk)
*
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
US7288390B2
(en)
*
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
WO2005056601A2
(en)
|
2003-12-05 |
2005-06-23 |
Schreiber John R |
Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse?
|
JP2004514423A
(ja)
*
|
2000-09-07 |
2004-05-20 |
シュライバー, ジョン アール. |
トランスジェニックxenomouse(登録商標)から獲得されるpeudomonasaeruginosalpsに対するヒト抗体
|
US7320792B2
(en)
|
2000-10-25 |
2008-01-22 |
Chugai Seiyaku Kabushiki Kaisha |
Preventives or remedies for psoriasis containing as the active ingredient IL-6 antagonist
|
KR100882029B1
(ko)
|
2000-11-17 |
2009-02-09 |
교와 핫꼬 기린 가부시키가이샤 |
클로닝된 트랜스제닉 유제류에서 이종 (사람)면역글로블린의 발현
|
AU1994402A
(en)
|
2000-11-28 |
2002-06-11 |
Mediummune Inc |
Methods of administering/dosing anti-rsv antibodies for prophylaxis and treatment
|
CA2430379A1
(en)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Endogenous retroviruses up-regulated in prostate cancer
|
DK1355919T3
(da)
|
2000-12-12 |
2011-03-14 |
Medimmune Llc |
Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
|
CA2433800C
(en)
|
2001-01-05 |
2016-09-13 |
Pfizer Inc. |
Antibodies to insulin-like growth factor i receptor
|
JP3986439B2
(ja)
|
2001-02-07 |
2007-10-03 |
中外製薬株式会社 |
造血器腫瘍の治療剤
|
EP1366058B1
(de)
|
2001-02-09 |
2011-01-26 |
Human Genome Sciences, Inc. |
Humaner g-protein-chemokinrezeptor (ccr5) hdgnr10
|
US8981061B2
(en)
|
2001-03-20 |
2015-03-17 |
Novo Nordisk A/S |
Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
|
MXPA03008454A
(es)
|
2001-03-22 |
2004-06-30 |
Abbott Gmbh & Co Kg |
Animales transgenicos que expresan anticuerpos especificos para genes de interes y usos de los mismos.
|
UA80091C2
(en)
|
2001-04-02 |
2007-08-27 |
Chugai Pharmaceutical Co Ltd |
Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
AU2002303261A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
AU2002258728A1
(en)
|
2001-04-06 |
2002-10-21 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
ATE470676T1
(de)
|
2001-04-13 |
2010-06-15 |
Human Genome Sciences Inc |
Anti-vegf-2 antikörper
|
ES2192128B1
(es)
*
|
2001-04-27 |
2005-01-01 |
Universidad De Vigo |
Anticuerpo monoclonal humano que reconoce especificamente la molecula humana cd69, y su uso en terapia.
|
EP2009027B1
(de)
|
2001-04-27 |
2014-05-21 |
Kyowa Hakko Kirin Co., Ltd. |
Monoklonaler Antikörper gegen CD40
|
EP1463522A4
(de)
|
2001-05-16 |
2005-04-13 |
Einstein Coll Med |
Humane antipneumokokken-antikörper von nichthumanen tieren
|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
AU2002315857B2
(en)
|
2001-06-22 |
2007-07-26 |
Kaisha, Chugai Seiyaku Kabushiki |
Cell proliferation inhibitors containing anti-glypican 3 antibody
|
TWI327597B
(en)
|
2001-08-01 |
2010-07-21 |
Centocor Inc |
Anti-tnf antibodies, compositions, methods and uses
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
DK2319301T3
(en)
|
2001-11-30 |
2017-12-04 |
Amgen Fremont Inc |
Transgenic animals with human Ig lambda light chain genes
|
WO2005077042A2
(en)
|
2004-02-09 |
2005-08-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2277910A1
(de)
|
2001-12-21 |
2011-01-26 |
Human Genome Sciences, Inc. |
Albumin Fusionsproteine
|
WO2003068259A1
(en)
|
2002-02-14 |
2003-08-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody-containing solution pharmaceuticals
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
CA2479730A1
(en)
|
2002-03-21 |
2003-10-02 |
Sagres Discovery, Inc. |
Novel compositions and methods in cancer
|
AU2003220930A1
(en)
|
2002-03-29 |
2003-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Emthod of screening transporter inhibitor
|
CN1326879C
(zh)
|
2002-03-29 |
2007-07-18 |
先灵公司 |
人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
AU2003226065B2
(en)
|
2002-04-12 |
2009-02-26 |
Ludwig Institute For Cancer Research, Ltd |
Recombinant anti-interleukin-9 antibodies
|
CN1652820A
(zh)
|
2002-04-12 |
2005-08-10 |
梅达雷克斯公司 |
使用ctla-4抗体的治疗方法
|
GB0208817D0
(en)
*
|
2002-04-17 |
2002-05-29 |
European Molecular Biology Lab Embl |
Method for producing monoclonal antibodies
|
KR20050000558A
(ko)
|
2002-05-17 |
2005-01-05 |
헤마테크, 엘엘씨 |
인간 항체를 제조할 수 있는 트랜스제닉 유제동물
|
CN101613405A
(zh)
|
2002-06-06 |
2009-12-30 |
肿瘤疗法科学股份有限公司 |
与人结肠癌相关的基因和多肽
|
CN100532549C
(zh)
|
2002-06-06 |
2009-08-26 |
肿瘤疗法科学股份有限公司 |
与人结肠癌相关的基因和多肽
|
EP1532161B1
(de)
|
2002-06-13 |
2012-02-15 |
Novartis Vaccines and Diagnostics, Inc. |
Vektoren zur expression von hml-2-polypeptiden
|
US7425618B2
(en)
|
2002-06-14 |
2008-09-16 |
Medimmune, Inc. |
Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
|
EA011686B1
(ru)
|
2002-07-15 |
2009-04-28 |
Уайт |
Способ модуляции развития и функций т-клеток-хелперов
|
EP2371389A3
(de)
|
2002-08-14 |
2012-04-18 |
MacroGenics, Inc. |
FC-Gamma-RIIB-spezifische Antikörper und Verwendungsverfahren davon
|
WO2004019966A1
(ja)
|
2002-08-27 |
2004-03-11 |
Chugai Seiyaku Kabushiki Kaisha |
タンパク質溶液製剤の安定化方法
|
EP1572946B1
(de)
|
2002-09-06 |
2012-03-14 |
Amgen, Inc. |
Therapeutischer menschlicher monoklonaler anti-il-1r1-antikörper
|
CA2496400A1
(en)
|
2002-09-09 |
2004-03-18 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
HUE027134T2
(en)
|
2002-09-11 |
2016-10-28 |
Chugai Pharmaceutical Co Ltd |
Method for protein purification
|
TW200418988A
(en)
|
2002-09-30 |
2004-10-01 |
Oncotherapy Science Inc |
Method for diagnosing prostate cancer
|
TW200413725A
(en)
|
2002-09-30 |
2004-08-01 |
Oncotherapy Science Inc |
Method for diagnosing non-small cell lung cancers
|
EA201492217A1
(ru)
*
|
2002-10-17 |
2015-06-30 |
Генмаб А/С |
Человеческие моноклональные антитела против cd20
|
SG146441A1
(en)
|
2002-10-22 |
2008-10-30 |
Eisai R&D Man Co Ltd |
Gene specifically expressed in postmitotic dopaminergic neuron precursor cells
|
EP1559786A4
(de)
|
2002-10-30 |
2006-01-11 |
Chugai Pharmaceutical Co Ltd |
Membranproteine aus mast zellen
|
CA2502490A1
(en)
|
2002-11-08 |
2004-05-27 |
Hematech, Llc |
Transgenic ungulates having reduced prion protein activity and uses thereof
|
CN1787837A
(zh)
|
2002-11-15 |
2006-06-14 |
希龙公司 |
防止和治疗癌转移以及与癌转移相关的骨质损失的方法
|
CA2537263C
(en)
|
2002-11-27 |
2017-05-30 |
Minerva Biotechnologies Corporation |
Techniques and compositions for the diagnosis and treatment of cancer (muc1)
|
EP1590364B1
(de)
|
2002-12-16 |
2011-10-05 |
Genmab A/S |
Humane monoklonale antikörper gegen interleukin 8 (il-8)
|
EP1589106B1
(de)
|
2002-12-29 |
2010-12-01 |
Toudai Tlo, Ltd. |
Adiponektin-rezeptor und dafür kodierendes gen
|
EP2368578A1
(de)
|
2003-01-09 |
2011-09-28 |
Macrogenics, Inc. |
Identifizierung und Herstellung von Antikörpern mit abweichenden FC-Regionen und Anwendungsverfahren dafür
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
EP1638587A4
(de)
|
2003-02-14 |
2007-04-18 |
Univ Missouri |
Empfängnisverhütende verfahren und zusammensetzungen betreffend proteasomale störung
|
EP2058408A3
(de)
|
2003-02-14 |
2009-09-09 |
Sagres Discovery, Inc. |
Therapeutische GPCR-Targets für Karzinome
|
ATE472338T1
(de)
|
2003-02-20 |
2010-07-15 |
Seattle Genetics Inc |
Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
|
SI1606409T1
(sl)
|
2003-03-19 |
2011-01-31 |
Biogen Idec Inc |
Vezavni protein receptorja Nogo
|
WO2004091510A2
(en)
|
2003-04-11 |
2004-10-28 |
Medimmune, Inc. |
Recombinant il-9 antibodies and uses thereof
|
GB2401040A
(en)
|
2003-04-28 |
2004-11-03 |
Chugai Pharmaceutical Co Ltd |
Method for treating interleukin-6 related diseases
|
EP2365001A3
(de)
*
|
2003-05-01 |
2012-03-28 |
Imclone LLC |
Vollständig humane Antikörper, die sich gegen den Wachstumfaktor-1-Rezeptor richten, der dem menschlichen Insulin ähnelt
|
US20070025961A1
(en)
*
|
2003-06-03 |
2007-02-01 |
Kenzo Bamba |
Composition for stabilizing survival of transplanted hematopoietic stem cell, kit for obtaining the composition, method of stabilizing survival of transplanted hematopoietic stem cell, human monoclonal antibody or human polyclonal antibody and method of producing the same, gene encoding human monoclonal antibody and transf
|
DE602004028249D1
(de)
|
2003-06-18 |
2010-09-02 |
Chugai Pharmaceutical Co Ltd |
Fucosetransporter
|
JP4489077B2
(ja)
*
|
2003-07-15 |
2010-06-23 |
アムジェン インコーポレイテッド |
選択的ngf経路インヒビターとしてのヒト抗ngf中和抗体
|
JP2008500005A
(ja)
|
2003-07-15 |
2008-01-10 |
バロス リサーチ インスティテュート |
癌及び感染症の免疫療法のための組成物及び方法
|
MEP31408A
(en)
*
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
HN2004000285A
(es)
|
2003-08-04 |
2006-04-27 |
Pfizer Prod Inc |
ANTICUERPOS DIRIGIDOS A c-MET
|
WO2005014854A1
(en)
|
2003-08-08 |
2005-02-17 |
Licentia, Ltd. |
Materials and methods for colorectal cancer screening, diagnosis, and therapy
|
WO2005014818A1
(ja)
|
2003-08-08 |
2005-02-17 |
Perseus Proteomics Inc. |
癌高発現遺伝子
|
EP1668111A4
(de)
|
2003-08-08 |
2008-07-02 |
Genenews Inc |
Osteoarthritis-biomarker und verwendungen davon
|
PT1656391E
(pt)
|
2003-08-13 |
2010-12-06 |
Pfizer Prod Inc |
Anticorpos humanos modificados contra igf-ir
|
AR045563A1
(es)
|
2003-09-10 |
2005-11-02 |
Warner Lambert Co |
Anticuerpos dirigidos a m-csf
|
AU2003271174A1
(en)
|
2003-10-10 |
2005-04-27 |
Chugai Seiyaku Kabushiki Kaisha |
Double specific antibodies substituting for functional protein
|
WO2005035754A1
(ja)
|
2003-10-14 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
KR101225463B1
(ko)
|
2003-11-07 |
2013-01-24 |
임뮤넥스 코포레이션 |
인터류킨-4 수용체에 결합하는 항체
|
US20050100965A1
(en)
|
2003-11-12 |
2005-05-12 |
Tariq Ghayur |
IL-18 binding proteins
|
US7750123B2
(en)
|
2003-11-25 |
2010-07-06 |
Dana Farber Cancer Institute, Inc. |
Antibodies against SARS-CoV and methods of use thereof
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
EP2070947B1
(de)
|
2003-12-05 |
2014-06-11 |
multimmune GmbH |
Anti-Hsp70-Antikörper zur Therapie und Diagnose
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
CA2550651C
(en)
|
2003-12-23 |
2018-01-23 |
Tanox, Inc. |
Novel anti-il 13 antibodies and uses thereof
|
PT1704166E
(pt)
|
2004-01-07 |
2015-09-04 |
Novartis Vaccines & Diagnostic |
Anticorpo monoclonal específico de m-csf e respetivos usos
|
PT2177537E
(pt)
|
2004-01-09 |
2011-12-13 |
Pfizer |
Anticorpos contra madcam
|
TW200600785A
(en)
|
2004-03-23 |
2006-01-01 |
Oncotherapy Science Inc |
Method for diagnosing non-small cell lung cancer
|
CA2562771C
(en)
|
2004-04-12 |
2013-04-09 |
Medimmune, Inc. |
Anti-il-9 antibody formulations and uses thereof
|
JP2007533328A
(ja)
|
2004-04-22 |
2007-11-22 |
キリンホールディングス株式会社 |
トランスジェニック動物及びその用途
|
US7491868B2
(en)
*
|
2004-04-30 |
2009-02-17 |
The General Hospital Corporation |
Mannose binding lectin knock-out mice and methods of use thereof
|
WO2005116657A2
(en)
|
2004-05-24 |
2005-12-08 |
Universität Zu Köln |
Identification of ergothioneine transporter and therapeutic uses thereof
|
US9228008B2
(en)
|
2004-05-28 |
2016-01-05 |
Idexx Laboratories, Inc. |
Canine anti-CD20 antibodies
|
DK1773384T3
(en)
|
2004-06-01 |
2015-11-23 |
Us Agriculture |
GM swine influenza virus and uses thereof
|
EP1602926A1
(de)
|
2004-06-04 |
2005-12-07 |
University of Geneva |
Neue Mittel und Verfahren zur Behandlung von Gehörverlust oder Tinnitus
|
ES2395094T3
(es)
|
2004-06-24 |
2013-02-08 |
Biogen Idec Ma Inc. |
Tratamiento de afecciones que implican la desmielinización
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
JP2008506681A
(ja)
|
2004-07-16 |
2008-03-06 |
ファイザー・プロダクツ・インク |
抗igf−1r抗体を用いる非血液性の悪性腫瘍の併用療法
|
US20060024677A1
(en)
|
2004-07-20 |
2006-02-02 |
Morris David W |
Novel therapeutic targets in cancer
|
CN101027390B
(zh)
|
2004-07-22 |
2012-12-12 |
卫材R&D管理有限公司 |
Lrp4/Corin多巴胺能神经元祖细胞标志物
|
CN101014245A
(zh)
|
2004-08-03 |
2007-08-08 |
比奥根艾迪克Ma公司 |
神经元功能中的taj
|
ES2414460T3
(es)
|
2004-08-04 |
2013-07-19 |
Amgen Inc. |
Anticuerpos para Dkk-1
|
WO2006023544A2
(en)
|
2004-08-16 |
2006-03-02 |
Quark Biotech, Inc. |
Therapeutic uses of inhibitors of rtp801
|
CA2486285C
(en)
|
2004-08-30 |
2017-03-07 |
Viktor S. Goldmakher |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
US20060051347A1
(en)
|
2004-09-09 |
2006-03-09 |
Winter Charles M |
Process for concentration of antibodies and therapeutic products thereof
|
WO2006034292A2
(en)
|
2004-09-21 |
2006-03-30 |
Medimmune, Inc. |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
EP1805222B1
(de)
|
2004-10-01 |
2011-02-02 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
|
AU2005299355A1
(en)
|
2004-10-27 |
2006-05-04 |
Medimmune, Llc |
Modulation of antibody specificity by tailoring the affinity to cognate antigens
|
GB0426146D0
(en)
|
2004-11-29 |
2004-12-29 |
Bioxell Spa |
Therapeutic peptides and method
|
CA2585104A1
(en)
|
2004-12-06 |
2006-06-15 |
Kirin Beer Kabushiki Kaisha |
Human monoclonal antibodies to influenza m2 protein and methods of making and using same
|
NZ555658A
(en)
|
2004-12-21 |
2010-04-30 |
Centocor Inc |
Anti-IL-12 antibodies, epitopes, compositions, methods and uses
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
US20090061485A1
(en)
|
2004-12-22 |
2009-03-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of Producing an Antibody Using a Cell in Which the Function of Fucose Transporter Is Inhibited
|
JP2008528486A
(ja)
|
2005-01-21 |
2008-07-31 |
ジェネンテック・インコーポレーテッド |
Her抗体の一定投薬
|
PA8660701A1
(es)
|
2005-02-04 |
2006-09-22 |
Pfizer Prod Inc |
Agonistas de pyy y sus usos
|
CN103497993A
(zh)
|
2005-02-07 |
2014-01-08 |
基因信息公司 |
轻度骨关节炎生物标志物及其用途
|
CN101175862A
(zh)
|
2005-02-10 |
2008-05-07 |
肿瘤疗法科学股份有限公司 |
诊断膀胱癌的方法
|
MX2007009810A
(es)
|
2005-02-14 |
2008-03-07 |
Wyeth Corp |
Uso de interleucina-17f en diagnostico y terapia de inflamacion de vias aereas.
|
MX2007009811A
(es)
|
2005-02-14 |
2007-09-07 |
Wyeth Corp |
Anticuerpos para interleucina-17f y otros antagonistas de la senalizacion de il 17f, y sus usos.
|
WO2006089133A2
(en)
|
2005-02-15 |
2006-08-24 |
Duke University |
Anti-cd19 antibodies and uses in oncology
|
EP1871807B1
(de)
|
2005-02-18 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen cxcr4 und anwendungsverfahren dafür
|
TWI406870B
(zh)
|
2005-02-21 |
2013-09-01 |
Chugai Pharmaceutical Co Ltd |
A method of making a protein using hamster IGF-1
|
ZA200707078B
(en)
|
2005-02-23 |
2008-11-26 |
Genentech Inc |
Extending time to disease progression or survival in cancer patients
|
WO2006096565A2
(en)
|
2005-03-04 |
2006-09-14 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
WO2006096461A2
(en)
|
2005-03-08 |
2006-09-14 |
Pharmacia & Upjohn Company Llc |
Composition comprising an antibody against macrophage colony-stimulating factor (m-csf) and a chelating agent
|
ES2720288T3
(es)
|
2005-03-30 |
2019-07-19 |
Minerva Biotechnologies Corp |
Proliferación de células que expresan MUC1
|
EP1875244B1
(de)
|
2005-03-30 |
2019-01-23 |
Minerva Biotechnologies Corporation |
Proliferation muc1 exprimierender zellen
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
WO2006110585A2
(en)
|
2005-04-07 |
2006-10-19 |
Novartis Vaccines And Diagnostics Inc. |
Cancer-related genes (prlr)
|
EP2062591A1
(de)
|
2005-04-07 |
2009-05-27 |
Novartis Vaccines and Diagnostics, Inc. |
CACNA1E in der Krebsdiagnose-Erkennung und -Behandlung
|
US20100003254A1
(en)
|
2005-04-08 |
2010-01-07 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody Substituting for Function of Blood Coagulation Factor VIII
|
GT200600148A
(es)
|
2005-04-14 |
2006-11-22 |
|
Metodos para el tratamiento y la prevencion de fibrosis
|
JP5838021B2
(ja)
|
2005-04-15 |
2015-12-24 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディとその使用
|
US8604174B2
(en)
|
2005-04-20 |
2013-12-10 |
Amgen Inc. |
High affinity fully human monoclonal antibodies to interleukin-8
|
US7807159B2
(en)
|
2005-04-25 |
2010-10-05 |
Amgen Fremont Inc. |
Antibodies to myostatin
|
CA2604357C
(en)
|
2005-04-26 |
2012-01-17 |
Pfizer Inc. |
P-cadherin antibodies
|
WO2006121852A2
(en)
|
2005-05-05 |
2006-11-16 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
NZ581779A
(en)
|
2005-05-17 |
2011-09-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism comprising interleukin-15 polypeptide and interleukin-15 receptor subunit A polypeptide complex
|
US7393919B2
(en)
|
2005-05-25 |
2008-07-01 |
Cure Dm, Inc. |
Peptides, derivatives and analogs thereof, and methods of using same
|
ME00261B
(me)
|
2005-05-27 |
2011-02-10 |
Biogen Idec Inc |
Tweak vezujuća antitijela
|
US8945543B2
(en)
|
2005-06-10 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
MX2007016343A
(es)
*
|
2005-06-22 |
2008-03-05 |
Genentech Inc |
Metodos y composiciones para ser blanco en ifnar2.
|
AU2006261920A1
(en)
|
2005-06-23 |
2007-01-04 |
Medimmune, Llc |
Antibody formulations having optimized aggregation and fragmentation profiles
|
BRPI0613387A2
(pt)
|
2005-07-08 |
2011-01-11 |
Biogen Idec Inc |
anticorpo isolado ou fragmento de ligação de antìgeno deste e o seu uso, polinucleotìdeo isolado, composição, vetor, célula hospedeira, anticorpo anti-sp35 e método para a produção do mesmo, polipeptìdeo isolado, método in vitro para redução da inibição do crescimento axonal e método in vitro para inibição do crescimento do colapso do cone
|
CN101273271A
(zh)
|
2005-07-27 |
2008-09-24 |
肿瘤疗法科学股份有限公司 |
***癌相关基因和多肽
|
US8652469B2
(en)
|
2005-07-28 |
2014-02-18 |
Novartis Ag |
M-CSF-specific monoclonal antibody and uses thereof
|
PT2573114T
(pt)
|
2005-08-10 |
2016-07-13 |
Macrogenics Inc |
Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
|
US9309315B2
(en)
|
2005-08-18 |
2016-04-12 |
Genmab A/S |
Therapy with CD4 binding peptides and radiation
|
PT1915397E
(pt)
|
2005-08-19 |
2015-04-30 |
Univ Pennsylvania |
Anticorpos antagonistas contra gdf-8 e utilizações no tratamento de ela e outros distúrbios associados a gdf-8
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
EP2500359A3
(de)
|
2005-08-19 |
2012-10-17 |
Abbott Laboratories |
Immunglobuline mit zweifacher variabler Domäne und ihre Verwendung
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
UY29783A1
(es)
|
2005-09-07 |
2007-04-30 |
Pfizer |
Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
|
ES2542501T3
(es)
|
2005-09-30 |
2015-08-06 |
Abbvie Deutschland Gmbh & Co Kg |
Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
AR058135A1
(es)
|
2005-10-21 |
2008-01-23 |
Chugai Pharmaceutical Co Ltd |
Agentes para el tratamiento de cardiopatias
|
US8239136B2
(en)
|
2005-10-21 |
2012-08-07 |
Genenews Inc. |
Method, computer system and computer-readable medium for determining a probability of colorectal cancer in a test subject
|
MX2008005764A
(es)
|
2005-11-04 |
2008-11-18 |
Biogen Idec Inc |
Metodos para promover el crecimiento de neuritas y la supervivencia en neuronas dopaminergicas.
|
DK2500030T4
(en)
|
2005-11-04 |
2018-10-29 |
Genentech Inc |
Use of complement pathway inhibitors for the treatment of eye diseases
|
EA014900B1
(ru)
|
2005-11-07 |
2011-02-28 |
Зе Скрипс Ресеч Инститьют |
Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
|
CA2626120C
(en)
|
2005-11-14 |
2012-12-04 |
Rinat Neuroscience Corp. |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
JP5398987B2
(ja)
|
2005-11-14 |
2014-01-29 |
セルミド リミテッド |
調節性t細胞の機能異常に基づく疾患の治療方法及び予防方法
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類cd134(ox40)之人類單株抗體及其製造及使用方法
|
EP1967209B1
(de)
|
2005-11-25 |
2012-06-06 |
Keio University |
Therapeutisches mittel gegen prostatakrebs
|
DK1963369T3
(da)
|
2005-11-28 |
2013-06-03 |
Zymogenetics Inc |
Il-21-antagonister
|
DK1954718T3
(en)
|
2005-11-30 |
2014-12-15 |
Abbvie Inc |
Anti-A-globulomer antibodies antigenbindingsgrupper thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods for producing said antibodies,
|
RU2432362C2
(ru)
|
2005-11-30 |
2011-10-27 |
Эбботт Лэборетриз |
Моноклональные антитела и их применения
|
MX2008007056A
(es)
|
2005-12-02 |
2008-11-12 |
Sinai School Medicine |
Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
|
KR101453570B1
(ko)
|
2005-12-02 |
2014-10-22 |
제넨테크, 인크. |
Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
|
EP2543384A3
(de)
|
2005-12-02 |
2013-04-10 |
Biogen Idec MA Inc. |
Behandlung von Zuständen mithilfe von Demyelinisation
|
EP1979379B1
(de)
|
2005-12-02 |
2013-09-18 |
Dana-Farber Cancer Institute |
Carboanhydrase ix (g250)-antikörper und verfahren zur verwendung davon
|
US8110194B2
(en)
|
2005-12-07 |
2012-02-07 |
Medarex, Inc. |
CTLA-4 antibody dosage escalation regimens
|
NZ568551A
(en)
*
|
2005-12-08 |
2012-03-30 |
Medarex Inc |
Human monoclonal antibodies to Fucosyl-GM1 and methods using anti-Fucosyl-GM1
|
JP5179373B2
(ja)
*
|
2005-12-15 |
2013-04-10 |
アストラゼネカ アクチボラグ |
癌を治療するためのアンジオポエチン−2アンタゴニストとVEGF−A、KDR、及び/又はFlt1アンタゴニストの組合せ
|
CN103396485B
(zh)
|
2005-12-15 |
2016-08-10 |
健泰科生物技术公司 |
靶向多聚泛蛋白的方法和组合物
|
US9084777B2
(en)
|
2005-12-28 |
2015-07-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilized antibody-containing formulations
|
US7745587B2
(en)
|
2005-12-30 |
2010-06-29 |
Dyax Corp. |
Antibodies that bind MMP-14
|
DOP2007000015A
(es)
|
2006-01-20 |
2007-08-31 |
Quark Biotech Inc |
Usos terapéuticos de inhibidores de rtp801
|
US8771686B2
(en)
|
2006-01-27 |
2014-07-08 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
|
EP2526968A3
(de)
|
2006-01-27 |
2013-05-22 |
Biogen Idec MA Inc. |
Nogo-Rezeptorantagonisten
|
US7803561B2
(en)
|
2006-02-06 |
2010-09-28 |
Rhode Island Hospital |
GPR30 estrogen receptor in breast cancers
|
WO2007106448A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Lexicon Genetics Incorporated |
Methods for making antibodies in genetically engineered mice
|
US8278421B2
(en)
|
2006-03-20 |
2012-10-02 |
Xoma Techolology Ltd. |
Human antibodies specific for gastrin materials and methods
|
CA2638774C
(en)
|
2006-03-31 |
2015-11-24 |
Medarex, Inc. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
EP3345616A1
(de)
|
2006-03-31 |
2018-07-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antikörpermodifizierungsverfahren zur reinigung von bispezifischem antikörper
|
CA2647846C
(en)
|
2006-03-31 |
2016-06-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for controlling blood pharmacokinetics of antibodies
|
WO2007123791A2
(en)
|
2006-03-31 |
2007-11-01 |
Dana-Farber Cancer Institute |
Methods of determining cellular chemosensitivity
|
EP2007428A2
(de)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Verfahren zur verwendung von boc/cdo zur modulation der hedgehog-signalisierung
|
CA2648644C
(en)
|
2006-04-07 |
2016-01-05 |
Osaka University |
Muscle regeneration promoter
|
US20100196377A1
(en)
|
2006-04-13 |
2010-08-05 |
Jantapour Mary J |
Methods of treating, diagnosing or detecting cancer
|
US20100080794A1
(en)
|
2006-04-14 |
2010-04-01 |
Takashi Tsuji |
Mutant polypeptide having effector function
|
MX2008015132A
(es)
|
2006-05-30 |
2008-12-10 |
Genentech Inc |
Anticuerpos e inmunoconjugados y sus usos.
|
KR20090027227A
(ko)
|
2006-06-06 |
2009-03-16 |
제넨테크, 인크. |
항-dll4 항체 및 이의 사용 방법
|
WO2007142325A1
(ja)
|
2006-06-08 |
2007-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
炎症性疾患の予防または治療剤
|
SG10201504662WA
(en)
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
DK2029173T3
(en)
|
2006-06-26 |
2016-11-07 |
Macrogenics Inc |
FC-RIIB-specific antibodies and methods of use thereof
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
WO2008054561A2
(en)
|
2006-07-11 |
2008-05-08 |
University Of Medicine And Dentistry Of New Jersey |
Proteins, nucleic acids encoding the same and associated methods of use
|
US20100150927A1
(en)
|
2006-07-13 |
2010-06-17 |
Chugai Seiyaku Kabushiki Kaisha |
Cell death inducer
|
WO2008010101A2
(en)
|
2006-07-18 |
2008-01-24 |
Sanofi-Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
JP5175729B2
(ja)
|
2006-07-21 |
2013-04-03 |
中外製薬株式会社 |
腎疾患治療剤
|
EP2057193B1
(de)
|
2006-08-04 |
2013-12-18 |
Novartis AG |
Ephb3-spezifischer antikörper und verwendungen davon
|
LT2511301T
(lt)
|
2006-08-04 |
2018-04-10 |
Medimmune Limited |
Žmogaus antikūnas prieš erbb2
|
WO2008020586A1
(en)
|
2006-08-14 |
2008-02-21 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-desmoglein-3 antibody
|
SI2059535T1
(sl)
|
2006-08-18 |
2014-03-31 |
Novartis Ag |
Za prlr specifiäśno protitelo in njegove uporabe
|
AU2007290570C1
(en)
|
2006-08-28 |
2013-08-15 |
Kyowa Kirin Co., Ltd. |
Antagonistic human LIGHT-specific human monoclonal antibodies
|
EP2471816A1
(de)
|
2006-08-30 |
2012-07-04 |
Genentech, Inc. |
Multispezifische Antikörper
|
JP5087625B2
(ja)
*
|
2006-09-01 |
2012-12-05 |
セラピューティック・ヒューマン・ポリクローナルズ・インコーポレーテッド |
非ヒトトランスジェニック動物におけるヒトまたはヒト化免疫グロブリンの発現強化
|
US20090053210A1
(en)
|
2006-09-01 |
2009-02-26 |
Roland Buelow |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
ES2817756T3
(es)
|
2006-09-08 |
2021-04-08 |
Abbvie Bahamas Ltd |
Proteínas de unión a interleuquina-13
|
CA2662236A1
(en)
|
2006-09-12 |
2008-03-20 |
Genentech, Inc. |
Methods and compositions for the diagnosis and treatment of cancer
|
EP2083017A4
(de)
|
2006-09-14 |
2011-01-12 |
Med & Biological Lab Co Ltd |
Antikörper mit verbesserter adcc-wirkung und verfahren zu dessen herstellung
|
KR101161923B1
(ko)
|
2006-10-03 |
2012-07-03 |
유니버시티 오브 메디신 앤드 덴티스트리 오브 뉴 저지 |
Atap 펩티드, 상기 펩티드를 엔코딩하는 핵산 및 이들과 관련된 사용 방법
|
EP2083852B1
(de)
|
2006-10-04 |
2014-12-10 |
Dana-Farber Cancer Institute, Inc. |
Tumorimmunität
|
WO2008047723A1
(en)
|
2006-10-12 |
2008-04-24 |
Forerunner Pharma Research Co., Ltd. |
Diagnosis and treatment of cancer using anti-ereg antibody
|
WO2008045563A2
(en)
|
2006-10-12 |
2008-04-17 |
Wyeth |
Modification of ionic strength in antibody-solutions to reduce opalescence/aggregates
|
EP2407548A1
(de)
|
2006-10-16 |
2012-01-18 |
MedImmune, LLC |
Moleküle mit reduzierter Halbwertzeit, Zusammensetzungen und ihre Verwendung
|
EP1914242A1
(de)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Neue Antikörper gegen CD38 zur Behandlung von Krebs
|
EP2093237B1
(de)
|
2006-10-20 |
2015-12-30 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-hb-egf-antikörper als anti-krebs wirkstoff
|
JP5378795B2
(ja)
|
2006-10-20 |
2013-12-25 |
中外製薬株式会社 |
抗hb−egf抗体を有効成分として含む医薬組成物
|
LT2845866T
(lt)
|
2006-10-27 |
2017-07-10 |
Genentech, Inc. |
Antikūnai ir imunokonjugatai bei jų panaudojimas
|
CA2666317C
(en)
|
2006-11-03 |
2013-08-06 |
Wyeth |
Glycolysis-inhibiting substances in cell culture
|
EP2094733A1
(de)
|
2006-11-03 |
2009-09-02 |
U3 Pharma GmbH |
Fgfr4-antikörper
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
EP2101813B1
(de)
|
2006-11-27 |
2014-04-02 |
Patrys Limited |
Neues glykosyliertes zielpeptid in neoplastischen zellen
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
EP2687232A1
(de)
|
2006-12-06 |
2014-01-22 |
MedImmune, LLC |
Verfahren zur Behandlung von systemischem Lupus erythematodes
|
MX2009006034A
(es)
|
2006-12-07 |
2009-10-12 |
Novartis Ag |
Anticuerpos antagonistas contra ephb3.
|
WO2008072723A1
(ja)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
AU2007333805B2
(en)
|
2006-12-18 |
2013-07-25 |
Genentech, Inc. |
Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases
|
CN103405768A
(zh)
|
2006-12-20 |
2013-11-27 |
爱克索马技术有限公司 |
用于治疗IL-1β相关疾病的方法
|
PT2099826E
(pt)
|
2007-01-05 |
2014-01-09 |
Univ Zuerich |
Anticorpo anti-beta-amilóide e suas utilizações
|
WO2008081942A1
(ja)
|
2007-01-05 |
2008-07-10 |
The University Of Tokyo |
抗prg-3抗体を用いる癌の診断および治療
|
ES2673153T3
(es)
|
2007-01-09 |
2018-06-20 |
Biogen Ma Inc. |
Anticuerpos Sp35 y usos de los mismos
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
AU2008205512B2
(en)
|
2007-01-16 |
2014-06-12 |
Abbvie Inc. |
Methods for treating psoriasis
|
US9725514B2
(en)
|
2007-01-23 |
2017-08-08 |
Shinshu University |
Chronic rejection inhibitor
|
EP2119777A4
(de)
|
2007-02-09 |
2011-05-25 |
Eisai R&D Man Co Ltd |
Gaba-neuronen-vorläuferzellen-marker 65b13
|
BRPI0806403A2
(pt)
|
2007-02-09 |
2011-09-06 |
Genentech Inc |
anticorpo anti-robo4, usode um anticorpo e método de obtenção de imagem
|
WO2008101184A2
(en)
|
2007-02-16 |
2008-08-21 |
The Board Of Trustees Of Southern Illinois University |
Arl-1 specific antibodies
|
US8685666B2
(en)
|
2007-02-16 |
2014-04-01 |
The Board Of Trustees Of Southern Illinois University |
ARL-1 specific antibodies and uses thereof
|
ES2456961T3
(es)
*
|
2007-02-21 |
2014-04-24 |
University Of Massachusetts |
Anticuerpos humanos contra el virus de la hepatitis C (VHC), usos de los mismos
|
KR101508397B1
(ko)
|
2007-02-22 |
2015-04-08 |
제넨테크, 인크. |
염증성 장 질환의 검출 방법
|
JP5374360B2
(ja)
|
2007-02-27 |
2013-12-25 |
中外製薬株式会社 |
抗grp78抗体を有効成分として含む医薬組成物
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
PL2132573T3
(pl)
|
2007-03-02 |
2014-09-30 |
Genentech Inc |
Prognozowanie odpowiedzi na inhibitor dimeryzacji HER oparte na niskiej ekspresji HER3
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
EP3159355A1
(de)
|
2007-03-13 |
2017-04-26 |
Universität Zürich |
Monoklonale humane tumorspezifische antikörper
|
JP2010521180A
(ja)
|
2007-03-14 |
2010-06-24 |
ノバルティス アーゲー |
癌を処置、診断または検出するためのapcdd1阻害剤
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
EP2142565A4
(de)
|
2007-03-29 |
2010-03-31 |
Abbott Lab |
Kristalline antikörper gegen humanes il-12
|
US20100209434A1
(en)
|
2007-03-30 |
2010-08-19 |
Medimmune, Llc |
Antibody formulation
|
SG182985A1
(en)
|
2007-04-02 |
2012-08-30 |
Amgen Fremont Inc |
Anti-ige antibodies
|
NO3072525T3
(de)
|
2007-05-14 |
2018-06-30 |
|
|
EP2158335A2
(de)
|
2007-05-21 |
2010-03-03 |
Genetech, Inc. |
Verfahren und zusammensetzungen zur identifizierung und behandlung von lupus
|
JP5117765B2
(ja)
|
2007-05-28 |
2013-01-16 |
国立大学法人 東京大学 |
抗robo1抗体を含むpet用腫瘍診断剤
|
AU2008259939B2
(en)
|
2007-06-01 |
2014-03-13 |
Open Monoclonal Technology, Inc. |
Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
|
ES2417148T3
(es)
|
2007-06-08 |
2013-08-06 |
Genentech, Inc. |
Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2
|
EP3424951A1
(de)
|
2007-06-21 |
2019-01-09 |
MacroGenics, Inc. |
Kovalente diabodies und deren verwendung
|
SG10202005450PA
(en)
|
2007-07-09 |
2020-07-29 |
Genentech Inc |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
PL2178921T3
(pl)
|
2007-07-17 |
2016-06-30 |
Squibb & Sons Llc |
Monoklonalne przeciwciała przeciwko glipikanowi-3
|
WO2009014263A1
(ja)
|
2007-07-26 |
2009-01-29 |
Osaka University |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
CA2696701C
(en)
|
2007-08-20 |
2017-01-24 |
Oncotherapy Science, Inc. |
Cdca1 peptide and pharmaceutical agent comprising the same
|
CN108117584B
(zh)
|
2007-08-20 |
2021-08-24 |
肿瘤疗法科学股份有限公司 |
Foxm1肽和包含foxm1肽的药剂
|
WO2009026303A1
(en)
|
2007-08-21 |
2009-02-26 |
Amgen Inc. |
Human c-fms antigen binding proteins
|
MX338474B
(es)
|
2007-08-29 |
2016-04-18 |
Sanofi Aventis |
Anticuerpos anti - cxcr5 humanizados, derivados de los mismos y su uso.
|
EP2570431A3
(de)
|
2007-08-30 |
2013-05-01 |
CureDM Group Holdings, LLC |
Zusammensetzungen und Verfahren zur Anwendung von Proinselzellpeptiden und Analoga Davon
|
EP2527369A3
(de)
|
2007-09-13 |
2012-12-19 |
University Of Zurich Prorektorat Forschung |
Monoklonaler amyloid-beta (abeta)-spezifischer Antikörper und seine Verwendung
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
CN106519025B
(zh)
|
2007-09-26 |
2021-04-23 |
中外制药株式会社 |
利用cdr的氨基酸取代来改变抗体等电点的方法
|
KR20100085067A
(ko)
|
2007-09-28 |
2010-07-28 |
추가이 세이야쿠 가부시키가이샤 |
혈장 중 반응속도가 개선된 항-글리피칸-3 항체
|
CN101815532B
(zh)
|
2007-10-02 |
2012-08-15 |
中外制药株式会社 |
以白细胞介素6受体抑制剂为有效成分的移植物抗宿主病治疗剂
|
US9683027B2
(en)
|
2007-10-15 |
2017-06-20 |
Chugai Seiyaku Kabushiki Kaisha |
Method for production of antibody
|
EP2050764A1
(de)
|
2007-10-15 |
2009-04-22 |
sanofi-aventis |
Neues polyvalentes bispezifisches Antikörperformat und Verwendung
|
SG185316A1
(en)
|
2007-10-19 |
2012-11-29 |
Immunas Pharma Inc |
ANTIBODY CAPABLE OF SPECIFICALLY BINDING TO Aβ OLIGOMER, AND USE THEREOF
|
EP2230300A4
(de)
|
2007-10-24 |
2012-08-08 |
Otsuka Chemical Holdings Co Ltd |
Polypeptid mit verbesserter effektorfunktion
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
EP2219452B1
(de)
|
2007-11-05 |
2015-10-14 |
MedImmune, LLC |
Verfahren zur behandlung von skleroderm
|
KR101620642B1
(ko)
|
2007-11-07 |
2016-05-12 |
제넨테크, 인크. |
항-cd40 항체를 사용한 치료에 대한 b-세포 림프종의 반응성 평가를 위한 방법 및 조성물
|
PT2514436T
(pt)
|
2007-11-07 |
2018-03-21 |
Genentech Inc |
Il-22 para utilização no tratamento de distúrbios microbianos
|
US8933202B2
(en)
|
2007-11-12 |
2015-01-13 |
U3 Pharma Gmbh |
AXL antibodies
|
AU2008321840B2
(en)
|
2007-11-14 |
2014-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Diagnosis and treatment of cancer using anti-GPR49 antibody
|
BRPI0820543A2
(pt)
|
2007-11-15 |
2015-06-16 |
Chugai Pharmaceutical Co Ltd |
Anticorpo monoclonal capaz de ligar a anexelekto, e uso do mesmo
|
CA2705923A1
(en)
|
2007-11-16 |
2009-05-22 |
Nuvelo, Inc. |
Antibodies to lrp6
|
EP2225275A4
(de)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
Proteinformulierung
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
ES2585480T3
(es)
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
US8431127B2
(en)
|
2007-12-05 |
2013-04-30 |
Chugai Seiyaku Kabushiki Kaisha |
Method for treating pruritus comprising administering an NR10 antagonist
|
WO2009079259A2
(en)
|
2007-12-06 |
2009-06-25 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against influenza virus and methods of use thereof
|
WO2009075344A1
(ja)
|
2007-12-12 |
2009-06-18 |
Japan As Represented By Director General Of Agency Of National Cancer Center |
M-csf受容体を分子標的とするmll白血病及びmoz白血病治療剤、およびその利用
|
DK2391650T3
(en)
|
2007-12-20 |
2015-01-12 |
Xoma Us Llc |
Methods of treating gout
|
EP2261254A3
(de)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Antiamyloide Antikörper und deren Verwendungen
|
AR069979A1
(es)
|
2007-12-26 |
2010-03-03 |
Biotest Ag |
Metodo para disminuir los efectos secundarios citotoxicos y mejorar la eficacia de los inmunoconjugados
|
CN101952315B
(zh)
|
2007-12-26 |
2015-04-01 |
生物测试股份公司 |
靶向cd138的试剂及其应用
|
KR101654822B1
(ko)
|
2007-12-26 |
2016-09-06 |
바이오테스트 아게 |
Cd138 표적성 면역접합체 및 이의 용도
|
CA2710483C
(en)
|
2007-12-26 |
2018-05-08 |
Biotest Ag |
Methods and agents for improving targeting of cd138 expressing tumor cells
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
US8962806B2
(en)
|
2007-12-28 |
2015-02-24 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
KR20100107501A
(ko)
|
2008-01-18 |
2010-10-05 |
메디뮨 엘엘씨 |
부위 특이적 접합을 위한 시스테인 조작 항체
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
BR122020023189B1
(pt)
|
2008-02-08 |
2022-02-01 |
Astrazeneca Ab |
Uso de uma composição farmacêutica compreendendo um anticorpo específico para ifnar1
|
CN102124105A
(zh)
|
2008-02-08 |
2011-07-13 |
伊缪纳斯制药株式会社 |
能够特异性结合Aβ寡聚体的抗体及其应用
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
JP5537441B2
(ja)
|
2008-03-04 |
2014-07-02 |
ファイザー・リミテッド |
慢性疼痛を治療する方法
|
EP2274333A4
(de)
|
2008-03-18 |
2011-06-15 |
Abbott Lab |
Verfahren zur behandlung von psoriasis
|
EP2260102A1
(de)
|
2008-03-25 |
2010-12-15 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tumorbehandlung mittels herunterregelung von frizzled-4 und/oder frizzled-1
|
NZ601815A
(en)
|
2008-03-31 |
2014-10-31 |
Genentech Inc |
Compositions and methods for treating and diagnosing asthma
|
CL2009000647A1
(es)
|
2008-04-04 |
2010-06-04 |
Chugai Pharmaceutical Co Ltd |
Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
|
WO2009124109A1
(en)
|
2008-04-04 |
2009-10-08 |
The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services |
Human monoclonal antibodies specific for cd22
|
EP2275443B1
(de)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
|
EP3348573B1
(de)
|
2008-04-25 |
2020-04-22 |
Dyax Corp. |
Methode zur herstellung von antikörper gegen fcrn
|
NZ588554A
(en)
|
2008-04-29 |
2013-03-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
EP2620448A1
(de)
|
2008-05-01 |
2013-07-31 |
Amgen Inc. |
Anti-hepcidin-antikörper und Verfahren zu ihrer Verwendung
|
CA2723197C
(en)
|
2008-05-02 |
2017-09-19 |
Seattle Genetics, Inc. |
Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
|
MY159667A
(en)
|
2008-05-09 |
2017-01-13 |
Abbvie Inc |
Antibodies to receptor of advanced glycation end products (rage) and uses thereof
|
WO2009148896A2
(en)
|
2008-05-29 |
2009-12-10 |
Nuclea Biotechnologies, LLC |
Anti-phospho-akt antibodies
|
EP2283862B1
(de)
|
2008-06-02 |
2018-08-08 |
The University of Tokyo |
Kombinationstherapie mit anti-mfg-e8 antikörper zur behandlung von krebs
|
MX2010013236A
(es)
|
2008-06-03 |
2011-02-24 |
Abbott Lab |
Inmunoglobulinas de dominio variable doble y usos de las mismas.
|
CN102112495A
(zh)
|
2008-06-03 |
2011-06-29 |
雅培制药有限公司 |
双重可变结构域免疫球蛋白及其用途
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
TWI528973B
(zh)
|
2008-06-05 |
2016-04-11 |
Chugai Pharmaceutical Co Ltd |
Nerve infiltration inhibitor
|
NZ589795A
(en)
|
2008-06-16 |
2013-02-22 |
Patrys Ltd |
Use of LM-1 antibody which binds to NONO/nmt55 protein to prevent metastasis
|
WO2009154025A1
(ja)
|
2008-06-20 |
2009-12-23 |
国立大学法人岡山大学 |
酸化LDL/β2GPI複合体に対する抗体及びその用途
|
EP2810654A1
(de)
|
2008-07-08 |
2014-12-10 |
AbbVie Inc. |
Prostaglandin-E2 bindende Proteine und ihre Verwendung
|
RU2011104348A
(ru)
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
DK2318832T3
(da)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder
|
JP5685535B2
(ja)
|
2008-08-18 |
2015-03-18 |
ファイザー インコーポレイティッド |
Ccr2に対する抗体
|
US20120128684A1
(en)
|
2008-08-25 |
2012-05-24 |
Burnham Institute For Medical Research |
Conserved Hemagglutinin Epitope, Antibodies to the Epitope and Methods of Use
|
CA2734905A1
(en)
|
2008-09-03 |
2010-03-11 |
Jenny M. Bostrom |
Multispecific antibodies
|
MX2011002478A
(es)
|
2008-09-07 |
2011-04-05 |
Glyconex Inc |
Anticuerpo anti-glucoesfingolipido tipo i extendido, derivados del mismo y su uso.
|
US20100075329A1
(en)
|
2008-09-23 |
2010-03-25 |
O'toole Margot |
Methods for predicting production of activating signals by cross-linked binding proteins
|
PL2346994T3
(pl)
|
2008-09-30 |
2022-04-19 |
Ablexis, Llc |
Myszy knock-in do wytwarzania chimerycznych przeciwciał
|
KR20110069144A
(ko)
|
2008-10-09 |
2011-06-22 |
미네르바 바이오테크놀로지 코포레이션 |
세포내에서 다능성을 유도하기 위한 방법
|
WO2010042747A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
SG10201605250SA
(en)
|
2008-10-14 |
2016-08-30 |
Genentech Inc |
Immunoglobulin variants and uses thereof
|
CA2741523C
(en)
|
2008-10-24 |
2022-06-21 |
Jonathan S. Towner |
Human ebola virus species and compositions and methods thereof
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
AU2009333791B2
(en)
|
2008-10-29 |
2013-04-04 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
US8415291B2
(en)
|
2008-10-31 |
2013-04-09 |
Centocor Ortho Biotech Inc. |
Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
|
WO2010052288A1
(en)
|
2008-11-07 |
2010-05-14 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Teneurin and cancer
|
EP2191843A1
(de)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Cyclophosphamid erkennen
|
EP2191841A1
(de)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Vincristin erkennen
|
EP2191842A1
(de)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Cytarabin erkennen
|
EP2191840A1
(de)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumorkombinationen mit Antikörpern, die insbesondere CD38 und Melphalan erkennen
|
CN104479018B
(zh)
|
2008-12-09 |
2018-09-21 |
霍夫曼-拉罗奇有限公司 |
抗-pd-l1抗体及它们用于增强t细胞功能的用途
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
SI2370466T1
(sl)
|
2008-12-19 |
2015-11-30 |
Biogen International Neuroscience Gmbh |
Človeška avtoprotitelesa proti alfa-sinukleinu
|
EP2377921B1
(de)
|
2008-12-22 |
2016-04-13 |
Eisai R&D Management Co., Ltd. |
Verfahren zur gewinnung von pankreasvorläuferzellen mittels neph3
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
CN102264759B
(zh)
|
2008-12-23 |
2016-05-11 |
弗·哈夫曼-拉罗切有限公司 |
与蛋白a的结合改变的免疫球蛋白变体
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
EP2377891B1
(de)
|
2008-12-26 |
2018-11-21 |
The University of Tokyo |
Diagnose und behandlung von krebs mit anti-lgr7-antikörper
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
CA2749572A1
(en)
|
2009-01-14 |
2010-07-22 |
Iq Therapeutics Bv |
Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
|
WO2010085510A1
(en)
|
2009-01-20 |
2010-07-29 |
Zadeh Homayoun H |
Antibody mediated osseous regeneration
|
US8852608B2
(en)
|
2009-02-02 |
2014-10-07 |
Medimmune, Llc |
Antibodies against and methods for producing vaccines for respiratory syncytial virus
|
US9085795B2
(en)
|
2009-02-04 |
2015-07-21 |
Molecular Innovations, Inc. |
Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
|
US8309530B2
(en)
|
2009-02-04 |
2012-11-13 |
Washington State University |
Compositions and methods for modulating ghrelin-mediated conditions
|
EP2396035A4
(de)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
Verwendung von antagonisten des b-lymphozyten-stimulatorproteins zur förderung von transplantationstoleranz
|
KR20180005752A
(ko)
*
|
2009-02-24 |
2018-01-16 |
에스바테크 - 어 노바티스 컴파니 엘엘씨 |
세포-표면 항원의 면역결합제를 동정하는 방법
|
JP5764071B2
(ja)
|
2009-02-24 |
2015-08-12 |
エスバテック − ア ノバルティスカンパニー エルエルシー |
細胞表面抗原のイムノバインダーを同定するための方法
|
RU2011140335A
(ru)
|
2009-03-05 |
2013-04-10 |
Эбботт Лэборетриз |
Связывающие il-17 белки
|
WO2010100247A1
(en)
|
2009-03-06 |
2010-09-10 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research |
Novel therapy for anxiety
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
MX2011009797A
(es)
|
2009-03-20 |
2012-01-12 |
Amgen Inc |
Inhibidores peptidicos de kv1.3 potentes selectivos.
|
US8597652B2
(en)
|
2009-03-20 |
2013-12-03 |
Genentech, Inc. |
Multispecific anti-HER antibodies
|
EP2411412B1
(de)
|
2009-03-24 |
2015-05-27 |
Teva Biopharmaceuticals USA, Inc. |
Humanisierte antikörper gegen licht und anwendungen davon
|
AU2010234849B2
(en)
|
2009-03-30 |
2017-06-22 |
Mount Sinai School Of Medicine |
Influenza virus vaccines and uses thereof
|
NZ595005A
(en)
|
2009-04-01 |
2014-04-30 |
Genentech Inc |
Treatment of insulin-resistant disorders
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
US8647623B2
(en)
|
2009-04-10 |
2014-02-11 |
Kyowa Hakko Kirin Co., Ltd |
Method for treatment of blood tumor using anti-TIM-3 antibody
|
EP2241323A1
(de)
|
2009-04-14 |
2010-10-20 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Tenascin-W und Hirnkrebs
|
KR20110138412A
(ko)
|
2009-04-16 |
2011-12-27 |
애보트 바이오테라퓨틱스 코포레이션 |
항-ΤΝF-α 항체 및 그의 용도
|
WO2010119704A1
(en)
|
2009-04-17 |
2010-10-21 |
Immunas Pharma, Inc. |
Antibodies that specifically bind to a beta oligomers and use thereof
|
JP5836929B2
(ja)
|
2009-04-18 |
2015-12-24 |
ジェネンテック, インコーポレイテッド |
抗cd40抗体を用いる治療に対するb細胞性リンパ腫の応答性を評価するための方法
|
CN104558179A
(zh)
|
2009-04-27 |
2015-04-29 |
协和发酵麒麟株式会社 |
用于治疗血液肿瘤的抗IL-3Rα抗体
|
KR20120051603A
(ko)
|
2009-05-01 |
2012-05-22 |
고쿠리츠다이가쿠호징 도쿄다이가쿠 |
항카드헤린 항체
|
SG10201707763PA
(en)
|
2009-05-05 |
2017-11-29 |
Amgen Inc |
FGF21 Mutants And Uses Thereof
|
US20120052069A1
(en)
|
2009-05-05 |
2012-03-01 |
Amgen Inc |
Fgf21 mutants and uses thereof
|
CA2800182A1
(en)
|
2009-05-26 |
2010-12-02 |
Mount Sinai School Of Medicine |
Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
|
WO2010137654A1
(ja)
|
2009-05-29 |
2010-12-02 |
株式会社未来創薬研究所 |
Egfファミリーリガンドのアンタゴニストを成分とする医薬組成物
|
US20100316639A1
(en)
|
2009-06-16 |
2010-12-16 |
Genentech, Inc. |
Biomarkers for igf-1r inhibitor therapy
|
WO2010148223A2
(en)
|
2009-06-17 |
2010-12-23 |
Facet Biotech Corporation |
Anti-vegf antibodies and their uses
|
RU2012101999A
(ru)
|
2009-06-22 |
2013-07-27 |
МЕДИММЬЮН, ЭлЭлСи |
РЕКОМБИНАНТНЫЕ УЧАСТКИ Fc ДЛЯ САЙТ-СПЕЦИФИЧЕСКОЙ КОНЪЮГАЦИИ
|
WO2011006001A1
(en)
|
2009-07-09 |
2011-01-13 |
Genentech, Inc. |
Animal model for the evaluation of adjuvant therapies of cancer
|
KR20120106935A
(ko)
|
2009-07-13 |
2012-09-27 |
제넨테크, 인크. |
암의 치료를 위한 진단 방법 및 조성물
|
WO2011014504A1
(en)
|
2009-07-27 |
2011-02-03 |
Mount Sinai School Of Medicine Of New York University |
Recombinant influenza virus vectors and uses thereof
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
JP5845180B2
(ja)
|
2009-07-30 |
2016-01-20 |
モウント シナイ スクール オフ メディシネ |
インフルエンザウイルス及びそれらの使用
|
TWI523661B
(zh)
|
2009-07-31 |
2016-03-01 |
Shin Maeda |
Anti-IL-6 receptor antibody in the manufacture of inhibitors of metastatic inhibition of lung cancer metastasis to the liver
|
US20110027275A1
(en)
|
2009-07-31 |
2011-02-03 |
Napoleone Ferrara |
Inhibition of tumor metastasis
|
AU2010280981B2
(en)
|
2009-08-05 |
2016-01-28 |
Nexigen Gmbh |
Human HCV-interacting proteins and methods of use
|
ES2614949T3
(es)
|
2009-08-06 |
2017-06-02 |
Immunas Pharma, Inc. |
Anticuerpos que se unen específicamente a oligómeros beta A y uso de los mismos
|
EP2462161B1
(de)
|
2009-08-06 |
2017-03-08 |
Immunas Pharma, Inc. |
Spezifisch an abeta-oligmomere bindende antikörper und ihre verwendung
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
RU2017138926A
(ru)
|
2009-08-11 |
2019-02-11 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
DK2464664T3
(da)
|
2009-08-13 |
2016-01-18 |
Crucell Holland Bv |
Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
|
RU2012109556A
(ru)
|
2009-08-14 |
2013-09-20 |
Дженентек, Инк. |
Биологические маркеры для мониторирования ответа пациента на антагонисты vegf
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
AU2010285974A1
(en)
|
2009-08-17 |
2012-03-22 |
Forerunner Pharma Research Co., Ltd. |
Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
|
WO2011024114A1
(en)
|
2009-08-25 |
2011-03-03 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Targeting extracellular matrix molecules for the treatment of cancer
|
EP2292266A1
(de)
|
2009-08-27 |
2011-03-09 |
Novartis Forschungsstiftung, Zweigniederlassung |
Behandlung von Krebs durch Modulation von Copine III
|
WO2011024113A1
(en)
|
2009-08-28 |
2011-03-03 |
Rinat Neuroscience Corporation |
Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
|
AU2010286518C1
(en)
|
2009-08-29 |
2015-08-27 |
Abbvie Inc. |
Therapeutic DLL4 binding proteins
|
SG178602A1
(en)
|
2009-09-01 |
2012-04-27 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011028945A1
(en)
|
2009-09-03 |
2011-03-10 |
Genentech, Inc. |
Methods for treating, diagnosing, and monitoring rheumatoid arthritis
|
US20110064670A1
(en)
|
2009-09-11 |
2011-03-17 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of responding to an anti-cancer agent
|
CN102630168A
(zh)
|
2009-09-14 |
2012-08-08 |
雅培制药有限公司 |
用于治疗银屑病的方法
|
CA2772670A1
(en)
|
2009-09-17 |
2011-03-24 |
F. Hoffmann-La Roche Ag |
Methods and compositions for diagnostics use in cancer patients
|
US20120244170A1
(en)
|
2009-09-22 |
2012-09-27 |
Rafal Ciosk |
Treating cancer by modulating mex-3
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
JP5885664B2
(ja)
|
2009-09-25 |
2016-03-15 |
ゾーマ テクノロジー リミテッド |
スクリーニング法
|
EP2305285A1
(de)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
|
CA2775880A1
(en)
|
2009-09-30 |
2011-04-07 |
Genentech, Inc. |
Anti-notch3 antagonist antibodies to treat gamma secretase inhibitor responsive and anti-notch1 antagonist antibody unresponsive t-cell leukemias
|
AR078470A1
(es)
|
2009-10-02 |
2011-11-09 |
Sanofi Aventis |
Anticuerpos que se unen especificamente al receptor epha2
|
JP5898082B2
(ja)
|
2009-10-07 |
2016-04-06 |
マクロジェニクス,インコーポレーテッド |
フコシル化程度の変更により改良されたエフェクター機能を示すFc領域含有ポリペプチドおよびその使用法
|
EP3839068A3
(de)
|
2009-10-07 |
2021-10-20 |
F. Hoffmann-La Roche AG |
Verfahren zur behandlung, diagnose und überwachung von lupus
|
EP2488658A4
(de)
|
2009-10-15 |
2013-06-19 |
Abbvie Inc |
Immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
WO2011045352A2
(en)
|
2009-10-15 |
2011-04-21 |
Novartis Forschungsstiftung |
Spleen tyrosine kinase and brain cancers
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
JO3244B1
(ar)
|
2009-10-26 |
2018-03-08 |
Amgen Inc |
بروتينات ربط مستضادات il – 23 البشرية
|
EP2494356B1
(de)
|
2009-10-26 |
2017-03-15 |
Genentech, Inc. |
Assays für den nachweis von für therapeutische antikörper gegen ige spezifische antikörper und ihre verwendung in der anaphylaxe
|
ES2639056T3
(es)
|
2009-10-28 |
2017-10-25 |
Abbvie Biotherapeutics Inc. |
Anticuerpos anti-EGFR y sus usos
|
UY32979A
(es)
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
US20120213801A1
(en)
|
2009-10-30 |
2012-08-23 |
Ekaterina Gresko |
Phosphorylated Twist1 and cancer
|
WO2011053707A1
(en)
|
2009-10-31 |
2011-05-05 |
Abbott Laboratories |
Antibodies to receptor for advanced glycation end products (rage) and uses thereof
|
WO2011060015A1
(en)
|
2009-11-11 |
2011-05-19 |
Genentech, Inc. |
Methods and compositions for detecting target proteins
|
GB0919751D0
(en)
|
2009-11-11 |
2009-12-30 |
King S College Hospital Nhs Fo |
Conjugate molecule
|
US9260517B2
(en)
|
2009-11-17 |
2016-02-16 |
Musc Foundation For Research Development |
Human monoclonal antibodies to human nucleolin
|
AR079114A1
(es)
|
2009-11-20 |
2011-12-28 |
Amgen Inc |
Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
US9175075B2
(en)
|
2009-12-08 |
2015-11-03 |
AbbVie Deutschland GmbH & Co. KG |
Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
|
WO2011071577A1
(en)
|
2009-12-11 |
2011-06-16 |
Genentech, Inc. |
Anti-vegf-c antibodies and methods using same
|
EP2513148B1
(de)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2-antikörper und ihre verwendung
|
AU2010339770B2
(en)
|
2009-12-21 |
2015-02-12 |
Genentech, Inc. |
Antibody formulation
|
DK2516465T3
(en)
|
2009-12-23 |
2016-06-06 |
Hoffmann La Roche |
ANTI-BV8 ANTIBODIES AND APPLICATIONS THEREOF
|
TWI505838B
(zh)
|
2010-01-20 |
2015-11-01 |
Chugai Pharmaceutical Co Ltd |
Stabilized antibody solution containing
|
JP5104996B2
(ja)
|
2010-01-29 |
2012-12-19 |
東レ株式会社 |
ポリ乳酸系樹脂シート
|
CN102892787B
(zh)
|
2010-02-10 |
2015-04-29 |
富士胶片Ri制药株式会社 |
放射性金属标记抗钙粘素抗体
|
MX342716B
(es)
|
2010-02-18 |
2016-10-11 |
Sinai School Medicine |
Vacunas para su uso en la profilaxis y tratamiento de la enfermedad del virus de influenza.
|
EP2536761B1
(de)
|
2010-02-19 |
2017-09-20 |
The Board Of Regents Of The University Of Oklahoma |
Monoklonale antikörper zur hemmung des wnt-signalisierungspfades sowie verfahren zu seiner herstellung und verwendung
|
BR112012021941A2
(pt)
|
2010-03-02 |
2022-02-01 |
Abbvie Inc |
Proteínas terapêuticas de ligação a dll4
|
JP5889181B2
(ja)
|
2010-03-04 |
2016-03-22 |
中外製薬株式会社 |
抗体定常領域改変体
|
WO2011107586A1
(en)
|
2010-03-05 |
2011-09-09 |
Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, |
Smoc1, tenascin-c and brain cancers
|
EP3248615A1
(de)
|
2010-03-30 |
2017-11-29 |
Mount Sinai School of Medicine of New York University |
Influenzavirus-impfstoffe und verwendungen davon
|
TWI667346B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的FcRn親和力之抗體
|
KR20210010942A
(ko)
|
2010-03-31 |
2021-01-28 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
US10338069B2
(en)
|
2010-04-12 |
2019-07-02 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
MX336196B
(es)
|
2010-04-15 |
2016-01-11 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
JP2013523184A
(ja)
|
2010-04-15 |
2013-06-17 |
アムジエン・インコーポレーテツド |
ヒトFGF受容体およびβ−KLOTHO結合性タンパク質
|
US20130034543A1
(en)
|
2010-04-19 |
2013-02-07 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear |
Modulating xrn1
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
IL208820A0
(en)
|
2010-10-19 |
2011-01-31 |
Rachel Teitelbaum |
Biologic female contraceptives
|
CN104777301B
(zh)
|
2010-05-10 |
2018-04-20 |
中央研究院 |
具有抗流感活性的扎那米韦膦酸酯同类物及流感病毒的奥司他韦易感性的测定
|
DK2571532T3
(en)
|
2010-05-14 |
2017-08-28 |
Abbvie Inc |
IL-1 BINDING PROTEINS
|
US20110293629A1
(en)
|
2010-05-14 |
2011-12-01 |
Bastid Jeremy |
Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011149051A1
(ja)
|
2010-05-28 |
2011-12-01 |
中外製薬株式会社 |
抗腫瘍t細胞応答増強剤
|
JP5904552B2
(ja)
|
2010-05-28 |
2016-04-13 |
国立研究開発法人国立がん研究センター |
膵癌治療剤
|
CA2800531C
(en)
|
2010-06-02 |
2021-05-25 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
WO2011153224A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of cancer
|
CA2795972A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
EP2580239A1
(de)
|
2010-06-10 |
2013-04-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Behandlung von krebs mittels modulation von mammalian-ste20-like-kinase 3
|
JP6029581B2
(ja)
|
2010-06-19 |
2016-11-24 |
メモリアル スローン−ケタリング キャンサー センター |
抗gd2抗体
|
ES2706913T3
(es)
|
2010-06-25 |
2019-04-01 |
Univ Aston |
Glucoproteínas que tienen propiedades de movilización de lípidos y usos terapéuticos de las mismas
|
WO2012006500A2
(en)
|
2010-07-08 |
2012-01-12 |
Abbott Laboratories |
Monoclonal antibodies against hepatitis c virus core protein
|
KR101896124B1
(ko)
|
2010-07-09 |
2018-09-07 |
얀센 백신스 앤드 프리벤션 비.브이. |
항-인간 호흡기 세포융합 바이러스(rsv) 항체 및 사용 방법
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
KR20130126576A
(ko)
|
2010-07-19 |
2013-11-20 |
에프. 호프만-라 로슈 아게 |
항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법
|
CN103180737A
(zh)
|
2010-07-19 |
2013-06-26 |
霍夫曼-拉罗奇有限公司 |
鉴定响应抗癌疗法的可能性升高的患者的方法
|
CA2807127C
(en)
|
2010-08-02 |
2019-02-12 |
Leslie S. Johnson |
Covalent diabodies and uses thereof
|
EP3252072A3
(de)
|
2010-08-03 |
2018-03-14 |
AbbVie Inc. |
Immunglobuline mit zweifacher variabler domäne und verwendungen davon
|
JP2013535692A
(ja)
|
2010-08-10 |
2013-09-12 |
アムジエン・インコーポレーテツド |
標的抗体に対する中和抗体検出用インビトロ二重機能標的結合アッセイ
|
EP2420250A1
(de)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4-Antikörper
|
MX358739B
(es)
|
2010-08-14 |
2018-09-03 |
Abbvie Inc Star |
Proteinas de union a amiloide beta.
|
PL3333188T3
(pl)
|
2010-08-19 |
2022-05-09 |
Zoetis Belgium S.A. |
Przeciwciała anty-ngf i ich zastosowanie
|
US9046513B2
(en)
|
2010-08-26 |
2015-06-02 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
WO2012025636A1
(en)
|
2010-08-27 |
2012-03-01 |
University Of Zurich |
Method for target and drug validation in inflammatory and/or cardiovascular diseases
|
WO2012028697A1
(en)
|
2010-09-01 |
2012-03-08 |
Eth Zürich, Institute Of Molecular Biology And Biophysics |
Affinity purification system based on donor strand complementation
|
US20130171159A1
(en)
|
2010-09-10 |
2013-07-04 |
Brian Arthur Hemmings |
Phosphorylated twist1 and metastasis
|
JP6055412B2
(ja)
|
2010-09-17 |
2016-12-27 |
バクスアルタ ゲーエムベーハー |
弱酸性〜中性のpHにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
|
WO2012040518A2
(en)
|
2010-09-22 |
2012-03-29 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
EA031698B1
(ru)
|
2010-10-11 |
2019-02-28 |
Байоджен Интернэшнл Нейросайенз Гмбх |
Человеческие анти-тау антитела
|
CN106563128B
(zh)
|
2010-10-22 |
2020-05-22 |
西雅图遗传学公司 |
以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
|
KR20140014077A
(ko)
|
2010-10-25 |
2014-02-05 |
리전츠 오브 더 유니버스티 오브 미네소타 |
교모세포종의 치료를 위한 치료 조성물
|
AR083740A1
(es)
|
2010-10-27 |
2013-03-20 |
Amgen Inc |
Anticuerpos dkk1 (dickkopf-1) y metodos de uso
|
JP6006640B2
(ja)
|
2010-10-29 |
2016-10-12 |
株式会社ペルセウスプロテオミクス |
高い内在化能力を有する抗cdh3抗体
|
US20140093506A1
(en)
|
2010-11-15 |
2014-04-03 |
Marc Buehler |
Anti-fungal-agents
|
WO2012067176A1
(ja)
|
2010-11-17 |
2012-05-24 |
中外製薬株式会社 |
血液凝固第viii因子の機能を代替する機能を有する多重特異性抗原結合分子
|
CN108715614A
(zh)
|
2010-11-30 |
2018-10-30 |
中外制药株式会社 |
与多分子的抗原重复结合的抗原结合分子
|
CA2819530C
(en)
|
2010-11-30 |
2023-01-10 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
US9283271B2
(en)
|
2010-12-17 |
2016-03-15 |
Neurimmune Holding Ag |
Human anti-SOD1 antibodies
|
RU2603097C2
(ru)
|
2010-12-21 |
2016-11-20 |
Селексис Фармасьютикалс Корпорейшн |
Антитела к р-селектину и способы их применения и идентификации
|
EP2655417A2
(de)
|
2010-12-21 |
2013-10-30 |
AbbVie Inc. |
Il-1 alpha- und -beta-bispezifische immunglobuline mit zweifacher variabler domäne und ihre verwendung
|
TW201307388A
(zh)
|
2010-12-21 |
2013-02-16 |
Abbott Lab |
Il-1結合蛋白
|
CA2824279A1
(en)
|
2010-12-22 |
2012-06-28 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
AU2011352207B2
(en)
|
2010-12-31 |
2016-03-03 |
Bioatla, Llc |
Comprehensive monoclonal antibody generation
|
US20120171195A1
(en)
|
2011-01-03 |
2012-07-05 |
Ravindranath Mepur H |
Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
|
JP5299440B2
(ja)
|
2011-01-13 |
2013-09-25 |
横河電機株式会社 |
経路設定装置、経路設定方法、管理装置、管理システム、及び記録媒体
|
AU2012207366A1
(en)
|
2011-01-18 |
2013-07-11 |
Amgen Inc. |
Nav1.7 knockout mice and uses thereof
|
EP3763740A1
(de)
|
2011-01-26 |
2021-01-13 |
Celldex Therapeutics, Inc. |
Anti-kit-antikörper und verwendungen davon
|
WO2012104824A1
(en)
|
2011-02-04 |
2012-08-09 |
Ecole polytechnique fédérale de Lausanne (EPFL) |
Therapeutic antibodies targeting app-c99
|
WO2012113775A1
(en)
|
2011-02-21 |
2012-08-30 |
University Of Zurich |
Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
|
CA2827923C
(en)
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
CN103502472B
(zh)
|
2011-02-28 |
2017-06-06 |
弗·哈夫曼-拉罗切有限公司 |
生物标记物和用于预测对b‑细胞拮抗剂的响应的方法
|
WO2012118903A2
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
JP2014510730A
(ja)
|
2011-03-16 |
2014-05-01 |
サノフイ |
デュアルv領域抗体様タンパク質の使用
|
EP2500073A1
(de)
|
2011-03-17 |
2012-09-19 |
ChromaCon AG |
Verfahren zur Identifizierung und Reinigung von mehrfach spezifischen Polypeptiden
|
US20140010756A1
(en)
|
2011-03-18 |
2014-01-09 |
Kagoshima University |
Composition for treatment and diagnosis of pancreatic cancer
|
WO2012129520A1
(en)
|
2011-03-24 |
2012-09-27 |
Texas Tech University System |
Tcr mimic antibodies as vascular targeting tools
|
EP3825325A3
(de)
|
2011-03-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Retention antigenbindender moleküle im blutplasma und verfahren zur modifizierung von immunogenität
|
CN103826657A
(zh)
|
2011-04-04 |
2014-05-28 |
衣阿华大学研究基金会 |
改进疫苗免疫原性的方法
|
RU2625034C2
(ru)
|
2011-04-20 |
2017-07-11 |
МЕДИММЬЮН, ЭлЭлСи |
Антитела и другие молекулы, которые связывают в7-н1 и pd-1
|
US9062106B2
(en)
|
2011-04-27 |
2015-06-23 |
Abbvie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
CN107936121B
(zh)
|
2011-05-16 |
2022-01-14 |
埃泰美德(香港)有限公司 |
多特异性fab融合蛋白及其使用方法
|
US8975029B2
(en)
|
2011-05-19 |
2015-03-10 |
The Regents Of The University Of Michigan |
Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
AR086543A1
(es)
|
2011-05-25 |
2014-01-08 |
Bg Medicine Inc |
Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
|
EP2530088A1
(de)
|
2011-05-30 |
2012-12-05 |
Klinikum rechts der Isar der Technischen Universität München |
Mittel und Verfahren zur Diagnose und Behandlung von Multipler Sklerose
|
WO2012167039A1
(en)
|
2011-06-02 |
2012-12-06 |
Dyax Corp. |
Fc RECEPTOR BINDING PROTEINS
|
BR112013030958B1
(pt)
|
2011-06-03 |
2022-02-08 |
Xoma Technology Ltd |
Anticorpo que se liga ao fator de transformação de crescimento beta, composição farmacêutica, usos dos mesmos, molécula de ácido nucleico, vetor de expressão, e método para produção de um anticorpo
|
US9181553B2
(en)
|
2011-06-06 |
2015-11-10 |
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Method of treatment of breast cancers over-expressing the SHP2 signature genes
|
JP6305919B2
(ja)
|
2011-06-06 |
2018-04-04 |
プロセナ バイオサイエンシーズ リミテッド |
Mcamアンタゴニスト及び治療の方法
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
WO2012170740A2
(en)
|
2011-06-07 |
2012-12-13 |
University Of Hawaii |
Biomarker of asbestos exposure and mesothelioma
|
US9561274B2
(en)
|
2011-06-07 |
2017-02-07 |
University Of Hawaii |
Treatment and prevention of cancer with HMGB1 antagonists
|
CA2838211C
(en)
|
2011-06-10 |
2023-08-01 |
Medimmmune Limited |
Anti-pseudomonas psl binding molecules and uses thereof
|
CA2838340A1
(en)
|
2011-06-17 |
2012-12-20 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using clec-2
|
US20140120555A1
(en)
|
2011-06-20 |
2014-05-01 |
Pierre Fabre Medicament |
Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
|
DK2723379T3
(en)
|
2011-06-23 |
2018-10-15 |
Biogen Int Neuroscience Gmbh |
ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
|
RU2641256C2
(ru)
|
2011-06-30 |
2018-01-16 |
Чугаи Сейяку Кабусики Кайся |
Гетеродимеризованный полипептид
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
DE202011103324U1
(de)
|
2011-07-12 |
2012-01-02 |
Nekonal S.A.R.L. |
Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
|
KR20140061403A
(ko)
|
2011-07-13 |
2014-05-21 |
애브비 인코포레이티드 |
항―il―13 항체를 이용하여 천식을 치료하기 위한 방법 및 조성물
|
JP6176849B2
(ja)
|
2011-07-19 |
2017-08-09 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
UA117220C2
(uk)
|
2011-08-01 |
2018-07-10 |
Дженентек, Інк. |
Способи лікування раку з використанням антагоністів, що зв'язуються з віссю pd-1, і інгібіторів mek
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
EP2739652B1
(de)
|
2011-08-04 |
2017-04-05 |
Medizinische Universität Innsbruck |
Cahgt1p-hemmer zur verwendung bei der behandlung von kandidiose
|
EP2756094B1
(de)
|
2011-08-15 |
2017-12-27 |
Medlmmune, LLC |
Anti-b7-h4 antikörper und ihre verwendungen
|
MX2014001736A
(es)
|
2011-08-17 |
2014-03-31 |
Genentech Inc |
Inhibicion de angiogenesis en tumores refractarios.
|
EP2749572A4
(de)
|
2011-08-23 |
2015-04-01 |
Chugai Pharmaceutical Co Ltd |
Neuer anti-ddr1-antikörper mit antitumoraktivität
|
CA2848074A1
(en)
|
2011-09-09 |
2013-03-14 |
Medimmune Limited |
Anti-siglec-15 antibodies and uses thereof
|
IN2014CN02114A
(de)
|
2011-09-20 |
2015-05-29 |
Sinai School Medicine |
|
CN103827145A
(zh)
|
2011-09-21 |
2014-05-28 |
富士瑞必欧株式会社 |
相对于亲和性复合物的抗体
|
WO2013041687A1
(en)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Bispecific binding molecules for 5t4 and cd3
|
EP3628329B1
(de)
|
2011-09-30 |
2022-08-10 |
Dana-Farber Cancer Institute, Inc. |
Therapeutische peptide mit antikörpern, die an mhc-klasse-1-polypeptid-verwandte sequenz a (mica) binden
|
TW201817745A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之FcRn結合域的治療性抗原結合分子
|
CA2850194C
(en)
|
2011-09-30 |
2023-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting elimination of antigens
|
RU2732151C2
(ru)
|
2011-09-30 |
2020-09-11 |
Чугаи Сейяку Кабусики Кайся |
Библиотека зависимых от концентрации ионов связывающих молекул
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
CA2850322C
(en)
|
2011-09-30 |
2023-10-10 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule inducing immune response to target antigen
|
EP2764118A1
(de)
|
2011-10-05 |
2014-08-13 |
University of Bremen |
Wnt4 und med12 zur verwendung bei der diagnose und behandlung von tumorerkrankungen
|
US20150299313A1
(en)
|
2011-10-05 |
2015-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting clearance from plasma of antigen comprising suger chain receptor-binding domain
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
DK3216871T3
(da)
*
|
2011-10-17 |
2022-02-21 |
Regeneron Pharma |
Mus med indskrænket tung immunoglobulinkæde
|
DK2768851T3
(en)
|
2011-10-21 |
2017-09-18 |
Augurex Life Sciences Corp |
ANTIGENS DERIVED BY CITRULLINATED 14-3-3 AND APPLICATIONS THEREOF IN THE DIAGNOSIS OF RHEUMATOID ARTHRITIS
|
RU2014120981A
(ru)
|
2011-10-24 |
2015-12-10 |
Эббви Инк. |
Иммунные связывающие агенты против склеростина
|
BR112014009799A2
(pt)
|
2011-10-24 |
2017-06-13 |
Abbvie Inc |
imunoligantes dirigidos conra tnf
|
GB2496375A
(en)
*
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
WO2013063419A2
(en)
|
2011-10-28 |
2013-05-02 |
The Trustees Of The University Of Pennsylvania |
A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
|
KR102398736B1
(ko)
|
2011-10-31 |
2022-05-16 |
추가이 세이야쿠 가부시키가이샤 |
중쇄와 경쇄의 회합이 제어된 항원 결합 분자
|
RU2665810C2
(ru)
|
2011-10-31 |
2018-09-04 |
Дженентек, Инк. |
Содержащие антитела составы
|
WO2013067057A1
(en)
|
2011-11-01 |
2013-05-10 |
Bionomics, Inc. |
Anti-gpr49 antibodies
|
AU2012332593B2
(en)
|
2011-11-01 |
2016-11-17 |
Bionomics, Inc. |
Anti-GPR49 antibodies
|
CN104053671A
(zh)
|
2011-11-01 |
2014-09-17 |
生态学有限公司 |
治疗癌症的抗体和方法
|
EP2773373B1
(de)
|
2011-11-01 |
2018-08-22 |
Bionomics, Inc. |
Verfahren zur blockierung eines krebsstammzellenwachstums
|
WO2013067492A1
(en)
|
2011-11-03 |
2013-05-10 |
The Trustees Of The University Of Pennsylvania |
Isolated b7-h4 specific compositions and methods of use thereof
|
EP2776838A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Frühe diagnose neurodegenerativer erkrankungen
|
EP2776565A1
(de)
|
2011-11-08 |
2014-09-17 |
Quark Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen und zur behandlung von erkrankungen, störungen oder läsionen des nervensystems
|
US20140322216A1
(en)
|
2011-11-08 |
2014-10-30 |
The Trustees Of The University Of Pennsylvania |
Glypican-3-specific antibody and uses thereof
|
AU2012335247A1
(en)
|
2011-11-08 |
2014-05-29 |
Pfizer Inc. |
Methods of treating inflammatory disorders using anti-M-CSF antibodies
|
EP2776022A1
(de)
|
2011-11-08 |
2014-09-17 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
Neue behandlung für neurodegenerative erkrankungen
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
HUE051954T2
(hu)
|
2011-11-28 |
2021-03-29 |
Merck Patent Gmbh |
ANTI-PD-L1 ellenanyagok és alkalmazásaik
|
WO2013081143A1
(ja)
|
2011-11-30 |
2013-06-06 |
中外製薬株式会社 |
免疫複合体を形成する細胞内への運搬体(キャリア)を含む医薬
|
MX368200B
(es)
|
2011-12-08 |
2019-09-24 |
Amgen Inc |
Proteinas de union al antigeno lecitin colesterol aciltransferasas humanas agonistas y su uso en terapia.
|
MX358680B
(es)
|
2011-12-08 |
2018-08-31 |
Biotest Ag |
Usos de inmunoconjugados dirigidos a cd138.
|
EP2602621A1
(de)
|
2011-12-08 |
2013-06-12 |
Julius-Maximilians-Universität Würzburg |
LASP-1, neuer Harnmarker zur Erkennung eines Übergangszellenkarzinoms
|
EP3800200A1
(de)
|
2011-12-14 |
2021-04-07 |
AbbVie Deutschland GmbH & Co. KG |
Zusammensetzung und verfahren zur diagnose und behandlung von durch eisenmangel bedingten erkrankungen
|
MX356933B
(es)
|
2011-12-14 |
2018-06-20 |
Abbvie Deutschland |
Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
|
EP3050900A1
(de)
|
2011-12-19 |
2016-08-03 |
Xoma (Us) Llc |
Verfahren zur behandlung von akne
|
EP3539982A3
(de)
|
2011-12-23 |
2020-01-15 |
Pfizer Inc |
Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
|
EP2794660A2
(de)
|
2011-12-23 |
2014-10-29 |
Phenoquest AG |
Antikörper zur behandlung und diagnose von affektiven störungen und angstzuständen
|
ES2964168T3
(es)
|
2011-12-28 |
2024-04-04 |
Immunoqure Ag |
Anticuerpo anti-interleucina 22 (IL-22) y usos del mismo
|
TWI593705B
(zh)
|
2011-12-28 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Humanized anti-epiregulin antibody and cancer therapeutic agent containing the antibody as an active ingredient
|
CA2861610A1
(en)
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
WO2013102825A1
(en)
|
2012-01-02 |
2013-07-11 |
Novartis Ag |
Cdcp1 and breast cancer
|
US10774132B2
(en)
|
2012-01-09 |
2020-09-15 |
The Scripps Research Instittue |
Ultralong complementarity determining regions and uses thereof
|
CN104411717A
(zh)
|
2012-01-09 |
2015-03-11 |
斯克利普斯研究所 |
具有超长cdr3s的人源化抗体
|
US10800847B2
(en)
|
2012-01-11 |
2020-10-13 |
Dr. Mepur Ravindranath |
Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
|
US20130177574A1
(en)
|
2012-01-11 |
2013-07-11 |
Paul I. Terasaki Foundation Laboratory |
ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
|
MX356802B
(es)
|
2012-01-13 |
2018-06-13 |
Genentech Inc |
Marcadores biologicos para identificar pacientes para tratamiento con antagonistas de vegf.
|
WO2013107290A1
(en)
|
2012-01-20 |
2013-07-25 |
The Government of the Hong Kong Special Administrative Region of the People's Republic of China |
A novel paramyxovirus and uses thereof
|
AU2013211939C1
(en)
|
2012-01-27 |
2018-06-07 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
AU2013215332A1
(en)
|
2012-01-31 |
2014-09-04 |
Genentech, Inc. |
Anti-Ig-E M1' antibodies and methods using same
|
SG10201704849PA
(en)
|
2012-02-09 |
2017-07-28 |
Chugai Pharmaceutical Co Ltd |
Modified fc region of antibody
|
CA2864092C
(en)
|
2012-02-10 |
2021-06-29 |
Seattle Genetics, Inc. |
Detection and treatment of cd30+ cancers
|
EP2814844B1
(de)
|
2012-02-15 |
2017-08-02 |
Novo Nordisk A/S |
Antikörper, die den auslösenden rezeptor binden und blockieren, der auf myeloid-zellen-1 (trem-1) exprimiert ist
|
US9550830B2
(en)
|
2012-02-15 |
2017-01-24 |
Novo Nordisk A/S |
Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
|
EP2814842B1
(de)
|
2012-02-15 |
2018-08-22 |
Novo Nordisk A/S |
Antikörper die das peptidoglycan-erkennungs-protein erkennen
|
US20150201588A1
(en)
|
2012-02-22 |
2015-07-23 |
Amgen Inc. |
Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods
|
AU2013223087B2
(en)
|
2012-02-24 |
2018-02-22 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for promoting disappearance of antigen via FcgammaRIIb
|
CA2864177C
(en)
|
2012-03-01 |
2019-11-26 |
Amgen Research (Munich) Gmbh |
Prolonged half-life albumin-binding protein fused bispecific antibodies
|
UY34652A
(es)
*
|
2012-03-02 |
2013-09-02 |
Regeneron Pharma |
Anticuerpos humanos frente a toxinas de clostridium difficile
|
US9592289B2
(en)
|
2012-03-26 |
2017-03-14 |
Sanofi |
Stable IgG4 based binding agent formulations
|
MX370486B
(es)
|
2012-03-27 |
2019-12-16 |
Genentech Inc |
Composiciones, métodos y usos para asistir en el diagnóstico, pronóstico y tratamiento de la fibrosis pulmonar idiopática.
|
SG11201406079TA
(en)
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Diagnosis and treatments relating to her3 inhibitors
|
EP2832856A4
(de)
|
2012-03-29 |
2016-01-27 |
Chugai Pharmaceutical Co Ltd |
Anti-lamp5-antikörper und verwendung davon
|
EP2831112A1
(de)
|
2012-03-29 |
2015-02-04 |
Friedrich Miescher Institute for Biomedical Research |
Hemmung von interleukin 8 und/oder dessen rezeptor cxcrl bei der behandlung von brustkrebs mit her2/her3-überexpression
|
HUE037613T2
(hu)
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
CN104271157A
(zh)
|
2012-03-30 |
2015-01-07 |
霍夫曼-拉罗奇有限公司 |
用于治疗癌症的诊断方法和组合物
|
CN103382223B
(zh)
|
2012-04-01 |
2015-06-10 |
上海益杰生物技术有限公司 |
针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽
|
US9764041B2
(en)
|
2012-04-04 |
2017-09-19 |
Perseus Proteomics Inc. |
Drug conjugate comprising anti-CDH3 (P-cadherin) antibody
|
WO2013151649A1
(en)
|
2012-04-04 |
2013-10-10 |
Sialix Inc |
Glycan-interacting compounds
|
WO2013155447A1
(en)
|
2012-04-13 |
2013-10-17 |
Children's Medical Center Corporation |
Tiki inhibitors
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
CN110078818B
(zh)
|
2012-04-27 |
2023-12-29 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
WO2013166043A1
(en)
|
2012-05-02 |
2013-11-07 |
Children's Hospital Medical Center |
Rejuvenation of precursor cells
|
ES2718472T3
(es)
|
2012-05-03 |
2019-07-02 |
Fibrogen Inc |
Métodos para tratar fibrosis pulmonar idiopática
|
WO2013166290A1
(en)
|
2012-05-04 |
2013-11-07 |
Abbvie Biotherapeutics Inc. |
P21 biomarker assay
|
US9441045B2
(en)
|
2012-05-04 |
2016-09-13 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
|
EA030716B1
(ru)
|
2012-05-14 |
2018-09-28 |
Байоджен Ма Инк. |
Антагонисты lingo-2 для лечения заболеваний, в которых участвуют двигательные нейроны
|
AU2013263349B2
(en)
|
2012-05-17 |
2016-09-08 |
Extend Biosciences, Inc |
Carriers for improved drug delivery
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
WO2013177386A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Biotherapeutics Inc. |
Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
|
TWI617578B
(zh)
|
2012-05-30 |
2018-03-11 |
Chugai Pharmaceutical Co Ltd |
標的組織專一的抗原結合分子
|
ES2856272T3
(es)
|
2012-05-30 |
2021-09-27 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígenos para eliminar antígenos agregados
|
CA2874144C
(en)
|
2012-05-31 |
2023-12-19 |
Genentech, Inc. |
Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
|
US9617334B2
(en)
|
2012-06-06 |
2017-04-11 |
Zoetis Services Llc |
Caninized anti-NGF antibodies and methods thereof
|
WO2013187495A1
(ja)
|
2012-06-14 |
2013-12-19 |
中外製薬株式会社 |
改変されたFc領域を含む抗原結合分子
|
KR101704893B1
(ko)
|
2012-06-15 |
2017-02-08 |
화이자 인코포레이티드 |
Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
|
WO2014001482A1
(en)
|
2012-06-29 |
2014-01-03 |
Novartis Forschungsstiftung, Zweigniererlassung, Friedrich Miescher Institute For Biomedical Research |
Treating diseases by modulating a specific isoform of mkl1
|
US10656156B2
(en)
|
2012-07-05 |
2020-05-19 |
Mepur Ravindranath |
Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
|
WO2014006114A1
(en)
|
2012-07-05 |
2014-01-09 |
Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research |
New treatment for neurodegenerative diseases
|
WO2014006115A1
(en)
|
2012-07-06 |
2014-01-09 |
Novartis Ag |
Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction
|
WO2014011955A2
(en)
|
2012-07-12 |
2014-01-16 |
Abbvie, Inc. |
Il-1 binding proteins
|
EP2872526B1
(de)
|
2012-07-13 |
2020-04-01 |
The Trustees of the University of Pennsylvania |
Verstärkung der aktivität von car-t-zellen durch miteinführung eines bispezifischen antikörpers
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
US9547009B2
(en)
|
2012-08-21 |
2017-01-17 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
EP2889376A4
(de)
|
2012-08-24 |
2016-11-02 |
Chugai Pharmaceutical Co Ltd |
Maus-fc-rii-spezifischer fc-antikörper
|
TWI717591B
(zh)
|
2012-08-24 |
2021-02-01 |
日商中外製藥股份有限公司 |
FcγRIIb特異性Fc區域變異體
|
KR20150046316A
(ko)
|
2012-08-31 |
2015-04-29 |
이뮤노젠 아이엔씨 |
엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
|
AU2013308409A1
(en)
|
2012-08-31 |
2015-03-26 |
University Of Birmingham |
Target peptides for immunotherapy and diagnostics
|
EP2890782A1
(de)
|
2012-09-02 |
2015-07-08 |
AbbVie Inc. |
Verfahren zur steuerung einer proteinheterogenität
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
AU2013312529A1
(en)
|
2012-09-05 |
2015-04-16 |
The University Of Birmingham |
Target peptides for colorectal cancer therapy and diagnostics
|
TWI595007B
(zh)
|
2012-09-10 |
2017-08-11 |
Neotope Biosciences Ltd |
抗mcam抗體及相關使用方法
|
AU2013317985B2
(en)
|
2012-09-19 |
2019-06-13 |
Dana-Farber Cancer Institute, Inc. |
Dynamic BH3 profiling
|
EP2711016A1
(de)
|
2012-09-21 |
2014-03-26 |
Covagen AG |
Neue IL-17A-Verbindungsmoleküle und medizinische Verwendungen davon
|
TWI606066B
(zh)
|
2012-09-27 |
2017-11-21 |
中外製藥股份有限公司 |
FGFR3 Fusion Gene and Its Targeted Medicine
|
CN104937423B
(zh)
|
2012-09-28 |
2017-05-24 |
中外制药株式会社 |
凝血反应的评价方法
|
EP2904106A4
(de)
|
2012-10-01 |
2016-05-11 |
Univ Pennsylvania |
Zusammensetzungen und verfahren zum anzielung von stromazellen zur behandlung von krebs
|
NO2760138T3
(de)
|
2012-10-01 |
2018-08-04 |
|
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
US10253107B2
(en)
|
2012-10-26 |
2019-04-09 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
TW202014439A
(zh)
|
2012-11-01 |
2020-04-16 |
美商艾伯維有限公司 |
抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
|
RS57696B1
(sr)
|
2012-11-08 |
2018-12-31 |
Univ Miyazaki |
Antitelo sposobno da specifično prepozna transferinski receptor
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
CN110183534A
(zh)
|
2012-12-03 |
2019-08-30 |
诺夫免疫股份有限公司 |
抗cd47抗体及其使用方法
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
AU2013359419B2
(en)
|
2012-12-10 |
2018-03-15 |
Biogen Ma Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
WO2014093855A1
(en)
|
2012-12-13 |
2014-06-19 |
University Of Virginia Patent Foundation |
Target peptides for ovarian cancer therapy and diagnostics
|
NZ627796A
(en)
|
2012-12-18 |
2017-07-28 |
Icahn School Med Mount Sinai |
Influenza virus vaccines and uses thereof
|
WO2014100439A2
(en)
|
2012-12-19 |
2014-06-26 |
Amplimmune, Inc. |
B7-h4 specific antibodies, and compositions and methods of use thereof
|
JP6359031B2
(ja)
|
2012-12-21 |
2018-07-18 |
メディミューン,エルエルシー |
抗h7cr抗体
|
JP6284548B2
(ja)
|
2012-12-21 |
2018-02-28 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
ヒト抗タウ抗体
|
WO2014104165A1
(ja)
|
2012-12-27 |
2014-07-03 |
中外製薬株式会社 |
ヘテロ二量化ポリペプチド
|
EP3517545A1
(de)
|
2012-12-31 |
2019-07-31 |
Neurimmune Holding AG |
Rekombinante menschliche antikörper zur therapie und vorbeugung von erkrankungen im zusammenhang mit polyomavirus
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
EP2951199A4
(de)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusionsproteine zur modulation von regulatorischen und effektor-t-zellen
|
WO2014130923A2
(en)
|
2013-02-25 |
2014-08-28 |
Genentech, Inc. |
Methods and compositions for detecting and treating drug resistant akt mutant
|
AU2013381687A1
(en)
|
2013-03-12 |
2015-09-24 |
Abbvie Inc. |
Human antibodies that bind human TNF-alpha and methods of preparing the same
|
NZ711567A
(en)
|
2013-03-13 |
2020-04-24 |
Genentech Inc |
Antibody formulations
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
IL292978A
(en)
|
2013-03-13 |
2022-07-01 |
Univ California |
Preparations containing antibodies against cd-38 carfilzomib
|
RU2707092C2
(ru)
|
2013-03-13 |
2019-11-22 |
Дженентек, Инк. |
Составы со сниженным окислением
|
CA3135558A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Prevention of protein oxidation in a composition
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
WO2014159242A1
(en)
|
2013-03-14 |
2014-10-02 |
Novartis Ag |
Notch 3 mutants and uses thereof
|
WO2014143343A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbott Laboratories |
Hcv core lipid binding domain monoclonal antibodies
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
CA2906688A1
(en)
|
2013-03-14 |
2014-09-25 |
Parkash S. Gill |
Cancer treatment using antibodies that bind cell surface grp78
|
US20140271629A1
(en)
|
2013-03-14 |
2014-09-18 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
JP2016512241A
(ja)
|
2013-03-14 |
2016-04-25 |
アボット・ラボラトリーズAbbott Laboratories |
改良された抗体検出のためのhcvns3組換え抗原およびこの突然変異体
|
WO2014159960A1
(en)
|
2013-03-14 |
2014-10-02 |
Icahn School Of Medicine At Mount Sinai |
Antibodies against influenza virus hemagglutinin and uses thereof
|
MX362075B
(es)
|
2013-03-14 |
2019-01-07 |
Abbott Lab |
Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo.
|
MX368665B
(es)
|
2013-03-15 |
2019-10-10 |
Abbvie Biotherapeutics Inc |
Variantes de fc.
|
AR095374A1
(es)
|
2013-03-15 |
2015-10-14 |
Amgen Res (Munich) Gmbh |
Moléculas de unión para bcma y cd3
|
CN105121470A
(zh)
|
2013-03-15 |
2015-12-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
AU2014233478A1
(en)
|
2013-03-15 |
2015-09-24 |
Abbvie Biotechnology Ltd. |
Anti-CD25 antibodies and their uses
|
AU2014236986A1
(en)
|
2013-03-15 |
2015-09-03 |
Biogen Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US10167341B2
(en)
|
2013-03-15 |
2019-01-01 |
Memorial Sloan Kettering Cancer Center |
High affinity anti-GD2 antibodies
|
SG11201507359SA
(en)
|
2013-03-15 |
2015-10-29 |
Dana Farber Cancer Inst Inc |
Flavivirus neutralizing antibodies and methods of use thereof
|
AP2015008732A0
(en)
|
2013-03-15 |
2015-09-30 |
Amgen Inc |
Human pac1 antibodies
|
RU2015144020A
(ru)
|
2013-03-15 |
2017-04-21 |
Дженентек, Инк. |
Среды для культивирования клеток и способы получения антител
|
SG11201507367PA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Cell culture compositions with antioxidants and methods for polypeptide production
|
CN105324396A
(zh)
|
2013-03-15 |
2016-02-10 |
艾伯维公司 |
针对IL-1β和/或IL-17的双重特异性结合蛋白
|
EP2970908B1
(de)
|
2013-03-15 |
2019-12-25 |
Dana-Farber Cancer Institute, Inc. |
Therapeutische peptide
|
EA201890895A1
(ru)
|
2013-03-15 |
2019-02-28 |
Зинджения, Инк. |
Мультивалентные и моновалентные мультиспецифические комплексы и их применение
|
WO2014144553A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
SG11201508170TA
(en)
|
2013-04-02 |
2015-11-27 |
Chugai Pharmaceutical Co Ltd |
Fc REGION VARIANT
|
WO2014165818A2
(en)
|
2013-04-05 |
2014-10-09 |
T Cell Therapeutics, Inc. |
Compositions and methods for preventing and treating prostate cancer
|
WO2014169076A1
(en)
|
2013-04-09 |
2014-10-16 |
Annexon,,Inc. |
Methods of treatment for neuromyelitis optica
|
TWI679019B
(zh)
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗il-4/抗il-13之雙特異性抗體調配物
|
EP2981822B1
(de)
|
2013-05-06 |
2020-09-02 |
Scholar Rock, Inc. |
Zusammensetzungen und verfahren zur modulation von wachstumsfaktoren
|
CN104140974B
(zh)
|
2013-05-08 |
2017-09-29 |
科济生物医药(上海)有限公司 |
编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
|
US9989540B2
(en)
|
2013-05-10 |
2018-06-05 |
The Regents Of The University Of California |
Diagnostic and monitoring system for Huntington's disease
|
JP6537143B2
(ja)
|
2013-05-16 |
2019-07-03 |
国立大学法人京都大学 |
癌の予後を診断する方法
|
KR20160129698A
(ko)
|
2013-05-24 |
2016-11-09 |
메디뮨 엘엘씨 |
항-b7-h5 항체 및 이의 용도
|
WO2014197866A1
(en)
|
2013-06-06 |
2014-12-11 |
Igenica Biotherapeutics, Inc. |
Modified antibodies and related compounds, compositions, and methods of use
|
AU2014274660B2
(en)
|
2013-06-06 |
2019-05-16 |
Pierre Fabre Médicament |
Anti-C10orf54 antibodies and uses thereof
|
WO2014197885A2
(en)
|
2013-06-07 |
2014-12-11 |
Duke University |
Inhibitors of complement factor h
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
US9499628B2
(en)
|
2013-06-14 |
2016-11-22 |
Children's Hospital Medical Center |
Method of boosting the immune response in neonates
|
KR20160022354A
(ko)
|
2013-06-24 |
2016-02-29 |
추가이 세이야쿠 가부시키가이샤 |
인간화 항에피레귤린 항체를 유효성분으로서 포함하는 선암 이외의 비소세포폐암의 치료제
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP3013347B1
(de)
|
2013-06-27 |
2019-12-11 |
Academia Sinica |
Glykankonjugate und verwendung davon
|
ES2911663T3
(es)
|
2013-07-03 |
2022-05-20 |
Immunoqure Ag |
Anticuerpos humanos anti-IFN-alfa
|
CA2916521C
(en)
|
2013-07-09 |
2023-03-07 |
Annexon, Inc. |
Anti-complement factor c1q antibodies and uses thereof
|
TW202100181A
(zh)
|
2013-07-16 |
2021-01-01 |
美商建南德克公司 |
利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
|
US20160168231A1
(en)
|
2013-07-18 |
2016-06-16 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
EP3030902B1
(de)
|
2013-08-07 |
2019-09-25 |
Friedrich Miescher Institute for Biomedical Research |
Neues screening-verfahren zur behandlung von friedreich-ataxie
|
WO2015021308A1
(en)
|
2013-08-07 |
2015-02-12 |
Astute Medical, Inc. |
Assays for timp2 having improved performance in biological samples
|
DK3036320T3
(da)
|
2013-08-19 |
2021-07-12 |
Biogen Ma Inc |
Styring af proteinglycosylering ved hjælp af dyrkningsmedietilsætning og cellekulturprocesparametre
|
US10617755B2
(en)
|
2013-08-30 |
2020-04-14 |
Genentech, Inc. |
Combination therapy for the treatment of glioblastoma
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
US10456470B2
(en)
|
2013-08-30 |
2019-10-29 |
Genentech, Inc. |
Diagnostic methods and compositions for treatment of glioblastoma
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
JP6663852B2
(ja)
|
2013-09-19 |
2020-03-13 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
Bh3プロファイリングの方法
|
WO2015041310A1
(ja)
|
2013-09-20 |
2015-03-26 |
中外製薬株式会社 |
抗プロテインc抗体による出血性疾患の治療
|
SG11201602283UA
(en)
|
2013-09-27 |
2016-04-28 |
Genentech Inc |
Anti-pdl1 antibody formulations
|
KR102441231B1
(ko)
|
2013-09-27 |
2022-09-06 |
추가이 세이야쿠 가부시키가이샤 |
폴리펩티드 이종 다량체의 제조방법
|
EP3052640A2
(de)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Verwendung von metallionen zur modulation von proteinglykosylierungsprofilen rekombinanter proteine
|
EP3054973B1
(de)
|
2013-10-10 |
2020-12-02 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1-bindende proteine und verfahren zur verwendung davon
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
WO2015066027A2
(en)
|
2013-10-28 |
2015-05-07 |
Dots Devices, Inc. |
Allergen detection
|
AU2014342103B2
(en)
|
2013-10-31 |
2020-06-04 |
Sanofi-Aventis U.S. Llc. |
Specific anti-CD38 antibodies for treating human cancers
|
CN105793439B
(zh)
|
2013-11-06 |
2020-09-04 |
阿斯图特医药公司 |
以生物样品进行的针对igfbp7的具有改进的性能的测定
|
CN113307873A
(zh)
|
2013-11-11 |
2021-08-27 |
中外制药株式会社 |
含有改变了抗体可变区的抗原结合分子
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
TWI664331B
(zh)
|
2013-12-04 |
2019-07-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
WO2015085210A1
(en)
|
2013-12-06 |
2015-06-11 |
Dana-Farber Cancer Institute, Inc. |
Therapeutic peptides
|
JP2017502002A
(ja)
|
2013-12-09 |
2017-01-19 |
ニューヨーク・ユニバーシティ |
抗ブドウ球菌剤の食細胞送達用組成物及び方法
|
WO2015088346A1
(en)
|
2013-12-13 |
2015-06-18 |
Rijksuniversiteit Groningen |
Antibodies against staphylococcus aureus and uses thereof.
|
EP3527587A1
(de)
|
2013-12-17 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-l1-bindungsantagonisten
|
RU2719487C2
(ru)
|
2013-12-17 |
2020-04-17 |
Дженентек, Инк. |
Способы лечения рака с использованием антагонистов, связывающихся с компонентами сигнального пути pd-1, и таксанов
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
KR20230155605A
(ko)
|
2013-12-20 |
2023-11-10 |
제넨테크, 인크. |
이중 특이적 항체
|
WO2015095809A1
(en)
|
2013-12-20 |
2015-06-25 |
Biogen Idec Ma Inc. |
Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality
|
DK3087986T3
(da)
|
2013-12-27 |
2019-12-02 |
Chugai Pharmaceutical Co Ltd |
Mutant fgfr-gatekeepergen og aktivt stof rettet mod samme
|
AU2014370873B2
(en)
|
2013-12-27 |
2020-06-11 |
Chugai Seiyaku Kabushiki Kaisha |
Method for purifying antibody having low isoelectric point
|
EP2893939A1
(de)
|
2014-01-10 |
2015-07-15 |
Netris Pharma |
Anti-Netrin-1-Antikörper
|
CN104774264B
(zh)
|
2014-01-15 |
2018-09-14 |
上海易乐生物技术有限公司 |
抗人proBDNF单克隆抗体及其在疼痛中的作用
|
CA2937123A1
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2015121383A1
(en)
|
2014-02-12 |
2015-08-20 |
Michael Uhlin |
Bispecific antibodies for use in stem cell transplantation
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
US10279021B2
(en)
|
2014-03-14 |
2019-05-07 |
Dana-Faber Cancer Institute, Inc. |
Vaccine compositions and methods for restoring NKG2D pathway function against cancers
|
EP3119804A2
(de)
|
2014-03-19 |
2017-01-25 |
Dana-Farber Cancer Institute, Inc. |
Immungenetisch beschränkung der induzierung von antikörpern
|
LT3119431T
(lt)
|
2014-03-21 |
2024-03-12 |
Teva Pharmaceuticals International Gmbh |
Antagonistiniai antikūnai, nukreipti prieš peptidą, susijusį su kalcitonino genu, ir jų panaudojimo būdai
|
US10556945B2
(en)
|
2014-03-21 |
2020-02-11 |
Teva Pharmaceuticals International Gmbh |
Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
KR102352250B1
(ko)
|
2014-03-25 |
2022-01-17 |
제넨테크, 인크. |
세포 배양 배지에 사용하기 위한 폴록사머를 제조하는 방법
|
WO2015148915A1
(en)
|
2014-03-27 |
2015-10-01 |
Academia Sinica |
Reactive labelling compounds and uses thereof
|
SG11201607772WA
(en)
|
2014-03-31 |
2016-10-28 |
Debiopharm Int Sa |
Fgfr fusions
|
JP6588461B2
(ja)
|
2014-03-31 |
2019-10-09 |
ジェネンテック, インコーポレイテッド |
抗血管新生剤及びox40結合アゴニストを含む併用療法
|
CN106536556B
(zh)
|
2014-04-04 |
2020-02-07 |
生态学有限公司 |
结合lgr5的人源化抗体
|
WO2015164364A2
(en)
|
2014-04-25 |
2015-10-29 |
The Brigham And Women's Hospital, Inc. |
Methods to manipulate alpha-fetoprotein (afp)
|
EP3134111B1
(de)
|
2014-04-25 |
2022-06-08 |
Dana-Farber Cancer Institute, Inc. |
Mers-coronavirus-neutralisierende antikörper und verfahren zu ihrer verwendung
|
AU2015254596B2
(en)
|
2014-04-30 |
2020-10-22 |
Klinikum Rechts Der Isar Der Technischen Universitat Munchen |
Diagnosis of multiple sclerosis
|
GB2541599B
(en)
|
2014-05-14 |
2020-05-20 |
Carsgen Therapeutics Ltd |
Nucleic acid for coding chimeric antigen receptor protein and T lymphocyte for expression of chimeric antigen receptor protein
|
US20170267780A1
(en)
|
2014-05-16 |
2017-09-21 |
Medimmune, Llc |
Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
|
AU2015259053B2
(en)
|
2014-05-16 |
2020-12-24 |
Amgen Inc. |
Assay for detecting Th1 and Th2 cell populations
|
WO2015179627A1
(en)
|
2014-05-21 |
2015-11-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer with anti bip or anti mica antibodies
|
US10005847B2
(en)
|
2014-05-27 |
2018-06-26 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP6894239B2
(ja)
|
2014-05-27 |
2021-06-30 |
アカデミア シニカAcademia Sinica |
増強された抗体の有効性のための普遍的グリコフォームに関する組成物および方法
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
WO2015189816A1
(en)
|
2014-06-13 |
2015-12-17 |
Friedrich Miescher Institute For Biomedical Research |
New treatment against influenza virus
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
WO2015198202A1
(en)
|
2014-06-23 |
2015-12-30 |
Friedrich Miescher Institute For Biomedical Research |
Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas
|
US20170165261A1
(en)
|
2014-07-01 |
2017-06-15 |
Brian Arthur Hemmings |
Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma
|
WO2016007752A1
(en)
|
2014-07-09 |
2016-01-14 |
Genentech, Inc. |
Ph adjustment to improve thaw recovery of cell banks
|
EP3169801A1
(de)
|
2014-07-14 |
2017-05-24 |
F. Hoffmann-La Roche AG |
Diagnostische verfahren und zusammensetzungen zur behandlung von glioblastomen
|
JP6673896B2
(ja)
|
2014-07-15 |
2020-03-25 |
ジェネンテック, インコーポレイテッド |
Pd−1軸結合アンタゴニスト及びmek阻害剤を使用した癌を処置するための組成物
|
MX2017000484A
(es)
|
2014-07-17 |
2017-05-01 |
Novo Nordisk As |
Mutagenesis dirigida al sitio anticuerpos receptor desencadenante expresado en las celulas mieloides de tipo 1 (trem-1) para reducir la viscosidad.
|
CN112979828A
(zh)
|
2014-07-17 |
2021-06-18 |
恺兴生命科技(上海)有限公司 |
靶向cld18a2的t淋巴细胞及其制备方法和应用
|
WO2018140026A1
(en)
|
2017-01-27 |
2018-08-02 |
Memorial Sloan Kettering Cancer Center |
Bispecific her2 and cd3 binding molecules
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
TW201609811A
(zh)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
具有增強之組織分布之雙特異性單鏈抗體構築體
|
AR101936A1
(es)
|
2014-07-31 |
2017-01-25 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos de cadena sencilla biespecífica específicos para especies cruzadas optimizadas
|
WO2016023019A2
(en)
|
2014-08-08 |
2016-02-11 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
WO2016025880A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
JP6858559B2
(ja)
|
2014-08-20 |
2021-04-14 |
中外製薬株式会社 |
蛋白質溶液の粘度測定方法
|
EP3183002B1
(de)
|
2014-08-21 |
2021-03-03 |
Walter Reed Army Institute of Research |
Monoklonale antikörper zur behandlung mikrobieller infektionen
|
KR20240011258A
(ko)
|
2014-09-02 |
2024-01-25 |
이뮤노젠 아이엔씨 |
항체 약물 컨쥬게이트 조성물의 제형화 방법
|
WO2016040369A2
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
TW201620938A
(zh)
|
2014-09-15 |
2016-06-16 |
安美基公司 |
雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途
|
US20160137727A1
(en)
|
2014-09-15 |
2016-05-19 |
Genentech, Inc. |
Antibody formulations
|
US10080790B2
(en)
|
2014-09-19 |
2018-09-25 |
The Regents Of The University Of Michigan |
Staphylococcus aureus materials and methods
|
WO2016046768A1
(en)
|
2014-09-24 |
2016-03-31 |
Friedrich Miescher Institute For Biomedical Research |
Lats and breast cancer
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
MY180054A
(en)
|
2014-09-30 |
2020-11-20 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
US10463732B2
(en)
|
2014-10-03 |
2019-11-05 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
|
WO2016057488A1
(en)
|
2014-10-06 |
2016-04-14 |
Dana-Farber Cancer Institute, Inc. |
Humanized cc chemokine receptor 4 (ccr4) antibodies and methods of use thereof
|
CA2964313C
(en)
|
2014-10-15 |
2023-03-14 |
Amgen Inc. |
Promoter and regulatory elements for improved expression of heterologous genes in host cells
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
US9789197B2
(en)
|
2014-10-22 |
2017-10-17 |
Extend Biosciences, Inc. |
RNAi vitamin D conjugates
|
US9616109B2
(en)
|
2014-10-22 |
2017-04-11 |
Extend Biosciences, Inc. |
Insulin vitamin D conjugates
|
WO2016065042A1
(en)
|
2014-10-22 |
2016-04-28 |
Extend Biosciences, Inc. |
Therapeutic vitamin d conjugates
|
AU2015339106B2
(en)
|
2014-10-31 |
2020-07-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of stimulating and expanding T cells
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
EA201790953A1
(ru)
|
2014-10-31 |
2017-10-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Изменение экспрессии гена в cart-клетках и их применения
|
SG11201703446RA
(en)
|
2014-10-31 |
2017-05-30 |
Abbvie Biotherapeutics Inc |
Anti-cs1 antibodies and antibody drug conjugates
|
WO2016073794A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Methods of producing two chain proteins in bacteria
|
MX2017005930A
(es)
|
2014-11-05 |
2017-06-30 |
Genentech Inc |
Metodo de produccion de proteinas de cadena doble en bacterias.
|
AU2015343029B2
(en)
|
2014-11-05 |
2021-07-29 |
Annexon, Inc. |
Humanized anti-complement factor C1q antibodies and uses thereof
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
US20160152720A1
(en)
|
2014-11-06 |
2016-06-02 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and tigit inhibitors
|
CA2967595A1
(en)
|
2014-11-12 |
2016-05-19 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
US9879087B2
(en)
|
2014-11-12 |
2018-01-30 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
EP3221360A1
(de)
|
2014-11-17 |
2017-09-27 |
F. Hoffmann-La Roche AG |
Kombinationstherapie mit ox40-bindungsagonisten und pd-1-achsenbindungsantagonisten
|
US10517898B2
(en)
|
2014-11-20 |
2019-12-31 |
The Regents Of The University Of California |
Compositions and methods related to hematologic recovery
|
ES2832802T3
(es)
|
2014-11-21 |
2021-06-11 |
Univ Maryland |
Sistemas de administración dirigida del particulado específico de una estructura
|
JP2017537929A
(ja)
|
2014-12-05 |
2017-12-21 |
ジェネンテック, インコーポレイテッド |
Pd−1軸アンタゴニスト及びhpk1アンタゴニストを用いたがん治療のための方法及び組成物
|
US20170182179A1
(en)
|
2014-12-09 |
2017-06-29 |
Abbvie Inc. |
Antibody Drug Conjugates with Cell Permeable BCL-XL Inhibitors
|
KR20170093943A
(ko)
|
2014-12-09 |
2017-08-16 |
애브비 인코포레이티드 |
낮은 세포 투과성을 갖는 bcl xl 억제 화합물 및 이를 포함하는 항체 약물 접합체
|
US10093733B2
(en)
|
2014-12-11 |
2018-10-09 |
Abbvie Inc. |
LRP-8 binding dual variable domain immunoglobulin proteins
|
PT3333191T
(pt)
|
2014-12-11 |
2020-12-15 |
Pf Medicament |
Anticorpos anti-c10orf54 e suas utilizações
|
JP6827928B2
(ja)
|
2014-12-19 |
2021-02-10 |
ユニヴェルシテ・ドゥ・ナント |
抗il−34抗体
|
US10221248B2
(en)
|
2014-12-22 |
2019-03-05 |
The Rockefeller University |
Anti-MERTK agonistic antibodies and uses thereof
|
AU2016205197B2
(en)
|
2015-01-08 |
2021-10-21 |
Biogen Ma Inc. |
LINGO-1 antagonists and uses for treatment of demyelinating disorders
|
JP7152156B2
(ja)
|
2015-01-14 |
2022-10-12 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
抗lapモノクローナル抗体による癌の処置
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
CA2974699A1
(en)
|
2015-01-23 |
2016-07-28 |
Icahn School Of Medicine At Mount Sinai |
Influenza virus vaccination regimens
|
US10342858B2
(en)
|
2015-01-24 |
2019-07-09 |
Academia Sinica |
Glycan conjugates and methods of use thereof
|
CN107430127B
(zh)
|
2015-01-24 |
2020-08-28 |
中央研究院 |
癌症标记及其使用方法
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
JP6942633B2
(ja)
|
2015-01-30 |
2021-09-29 |
アカデミア シニカAcademia Sinica |
抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法
|
EP4223873A3
(de)
|
2015-01-31 |
2023-09-06 |
The Trustees of the University of Pennsylvania |
Zusammensetzungen und verfahren zur t-zell-freisetzung von therapeutischen molekülen
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
KR20170110129A
(ko)
|
2015-02-05 |
2017-10-10 |
추가이 세이야쿠 가부시키가이샤 |
이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
|
CA2976074A1
(en)
|
2015-02-09 |
2016-08-18 |
Memorial Sloan Kettering Cancer Center |
Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
|
CN107405401B
(zh)
|
2015-02-26 |
2022-02-01 |
默克专利股份公司 |
用于治疗癌症的pd-1/pd-l1抑制剂
|
AU2016224409B2
(en)
|
2015-02-27 |
2021-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
SG10201907901XA
(en)
|
2015-03-03 |
2019-10-30 |
Kymab Ltd |
Antibodies, uses & methods
|
EP3265491A1
(de)
|
2015-03-03 |
2018-01-10 |
Xoma (Us) Llc |
Behandlung von postprandialer hyperinsulinämie und hyperglykämie nach bariatrischer chirurgie
|
KR20170125941A
(ko)
|
2015-03-06 |
2017-11-15 |
체에스엘 베링 리컴비넌트 퍼실리티 아게 |
개선된 반감기를 갖는 변형된 폰 빌레브란트 인자
|
RU2733496C2
(ru)
|
2015-03-16 |
2020-10-02 |
Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) |
Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
|
CN107667120B
(zh)
|
2015-03-17 |
2022-03-08 |
纪念斯隆-凯特林癌症中心 |
抗muc16抗体及其应用
|
EP3271397B1
(de)
|
2015-03-18 |
2021-03-03 |
The Johns Hopkins University |
Inhibitorischer monoklonaler antikörper gegen den kaliumkanal kcnk9
|
TR201904903T4
(tr)
|
2015-03-25 |
2019-05-21 |
Alexion Pharma Inc |
Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.
|
US20180074077A1
(en)
|
2015-03-25 |
2018-03-15 |
Alexion Pharmaceuticals, Inc. |
A method for measuring the protease activity of factor d of the alternative complement pathway
|
CN108136001B
(zh)
|
2015-04-03 |
2022-07-29 |
佐马技术有限公司 |
使用TGF-β抑制剂和PD-1抑制剂治疗癌症
|
WO2016164637A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Anti-sortilin antibodies and methods of use thereof
|
WO2016164608A1
(en)
|
2015-04-07 |
2016-10-13 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
EP3280730B1
(de)
|
2015-04-08 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Humanisierte monoklonale influenzaantikörper und verfahren zur verwendung davon
|
FI3283524T3
(fi)
|
2015-04-17 |
2023-05-05 |
Amgen Res Munich Gmbh |
Bispesifisiä vasta-ainekonstrukteja cdh3:lle ja cd3:lle
|
MX2017010734A
(es)
|
2015-04-17 |
2017-12-04 |
Hoffmann La Roche |
Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos.
|
KR20180018507A
(ko)
|
2015-04-20 |
2018-02-21 |
톨레로 파마수티컬스, 인크. |
미토콘드리아 프로파일링에 의한 알보시딥에 대한 반응 예측
|
JOP20200116A1
(ar)
|
2015-04-24 |
2017-06-16 |
Amgen Inc |
طرق لعلاج أو الوقاية من الصداع النصفي
|
US20180120297A1
(en)
|
2015-04-27 |
2018-05-03 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for assessing toxicity using dynamic bh3 profiling
|
KR20170138556A
(ko)
|
2015-05-01 |
2017-12-15 |
다나-파버 캔서 인스티튜트 인크. |
항ccr4 항체를 이용하여 사이토카인 발현을 매개하는 방법
|
EA201792451A1
(ru)
|
2015-05-07 |
2018-05-31 |
Агенус Инк. |
Антитела к ox40 и способы их применения
|
EP3936524A3
(de)
|
2015-05-11 |
2022-06-15 |
F. Hoffmann-La Roche AG |
Zusammensetzungen und verfahren zur behandlung von lupus nephritis
|
SI3294770T1
(sl)
|
2015-05-12 |
2021-01-29 |
F. Hoffmann-La Roche Ag |
Terapevtski in diagnostični postopki za raka
|
EP3294773A1
(de)
|
2015-05-15 |
2018-03-21 |
The General Hospital Corporation |
Antagonistische anti-tumor-nekrosefaktorrezeptorsuperfamilienantikörper
|
MX2017014645A
(es)
|
2015-05-18 |
2018-01-23 |
Tolero Pharmaceuticals Inc |
Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
|
EP4209228A1
(de)
|
2015-05-22 |
2023-07-12 |
Translational Drug Development, LLC |
Benzamid- und wirkstoffzusammensetzungen sowie verfahren zur verwendung
|
CR20170592A
(es)
|
2015-05-29 |
2018-02-13 |
Abbvie Inc |
Anticuerpos anti-cd40 y sus usos
|
RS60792B1
(sr)
|
2015-05-29 |
2020-10-30 |
Agenus Inc |
Anti-ctla-4 antitela i postupci za njihovu primenu
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
AU2016269839B2
(en)
|
2015-06-03 |
2021-07-08 |
The University Of Queensland |
Mobilizing agents and uses therefor
|
WO2016201389A2
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
CA2988982A1
(en)
|
2015-06-12 |
2016-12-15 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
EP3310810A1
(de)
|
2015-06-16 |
2018-04-25 |
Merck Patent GmbH |
Kombinationsbehandlungen mit pd-l1-antagonisten
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
MX2017016645A
(es)
|
2015-06-29 |
2018-11-09 |
Genentech Inc |
Anticuerpo anti-cd20 de tipo ii para su uso en el trasplante de órganos.
|
TW202346349A
(zh)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
WO2017024073A1
(en)
|
2015-08-03 |
2017-02-09 |
Tolero Pharmaceuticals, Inc. |
Combination therapies for treatment of cancer
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
JP2018532693A
(ja)
|
2015-08-06 |
2018-11-08 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
|
MA45352A
(fr)
|
2015-08-07 |
2018-06-13 |
Univ Birmingham |
Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3337822A1
(de)
|
2015-08-19 |
2018-06-27 |
Rutgers, The State University of New Jersey |
Neuartige verfahren zur erzeugung von antikörpern
|
PL3338094T3
(pl)
|
2015-08-20 |
2019-09-30 |
F. Hoffmann-La Roche Ag |
Test immunologiczny oparty na cząstkach z zastosowaniem pegylowanego swoistego względem analitu czynnika wiążącego
|
CA2996059A1
(en)
|
2015-08-28 |
2017-03-09 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
US10323091B2
(en)
|
2015-09-01 |
2019-06-18 |
Agenus Inc. |
Anti-PD-1 antibodies and methods of use thereof
|
EP3344806A4
(de)
|
2015-09-04 |
2019-03-20 |
OBI Pharma, Inc. |
Glycanarrays und verfahren zur verwendung
|
AU2016323440B2
(en)
|
2015-09-15 |
2023-07-13 |
Amgen Inc. |
Tetravalent bispecific and tetraspecific antigen binding proteins and uses thereof
|
CN108271372B
(zh)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
CA3000386A1
(en)
|
2015-09-30 |
2017-04-06 |
Merck Patent Gmbh |
Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer
|
AU2016332062A1
(en)
|
2015-10-01 |
2018-04-26 |
Amgen Inc. |
Treatment of bile acid disorders
|
KR20180068999A
(ko)
|
2015-10-06 |
2018-06-22 |
알렉터 엘엘씨 |
항-trem2 항체 및 그의 사용방법
|
WO2017072669A1
(en)
|
2015-10-28 |
2017-05-04 |
Friedrich Miescher Institute For Biomedical Research |
Tenascin-w and biliary tract cancers
|
AU2016343987B2
(en)
|
2015-10-29 |
2023-11-23 |
Alector Llc |
Anti-Siglec-9 antibodies and methods of use thereof
|
AR106543A1
(es)
|
2015-11-02 |
2018-01-24 |
Netris Pharma |
Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético
|
CN108350078A
(zh)
|
2015-11-03 |
2018-07-31 |
默克专利股份公司 |
用于提高肿瘤选择性和抑制的双特异性抗体及其用途
|
IL258768B2
(en)
|
2015-11-12 |
2023-11-01 |
Siamab Therapeutics Inc |
Compounds interacting with glycans and methods of use
|
JP6925278B2
(ja)
|
2015-11-18 |
2021-08-25 |
中外製薬株式会社 |
液性免疫応答の増強方法
|
EP3378487B1
(de)
|
2015-11-18 |
2022-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Kombinationstherapie mit t-zell-neuausrichtendem antigenbindendem molekül gegen zelle mit immunsuppressiver funktion
|
FI3380525T3
(fi)
|
2015-11-25 |
2024-01-30 |
Immunogen Inc |
Lääkeformulaatioita ja niiden käyttömenetelmiä
|
JP2019500327A
(ja)
|
2015-11-30 |
2019-01-10 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
JP2019501124A
(ja)
|
2015-11-30 |
2019-01-17 |
アッヴィ・インコーポレイテッド |
抗huLRRC15抗体薬物コンジュゲート及びその使用方法
|
ES2861449T3
(es)
|
2015-12-02 |
2021-10-06 |
Stcube & Co Inc |
Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
|
JP7227007B2
(ja)
|
2015-12-02 |
2023-02-21 |
ストサイエンシス, インコーポレイテッド |
グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体
|
MA43567A
(fr)
|
2015-12-15 |
2018-11-14 |
Amgen Inc |
Anticorps pacap et leurs utilisations
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
MA44154A
(fr)
|
2015-12-23 |
2018-10-31 |
Amgen Inc |
Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
|
US20200270363A1
(en)
|
2015-12-25 |
2020-08-27 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
CA3007491A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
WO2017114975A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating gastric cancer
|
US11760808B2
(en)
|
2015-12-31 |
2023-09-19 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating ovarian cancer
|
CA3009785A1
(en)
|
2015-12-31 |
2017-07-06 |
Progastrine Et Cancers S.A R.L. |
Compositions and methods for detecting and treating esophageal cancer
|
CN108700586A
(zh)
|
2015-12-31 |
2018-10-23 |
Syncerus有限责任公司 |
用于评估癌症发生的风险的组合物和方法
|
WO2017120536A1
(en)
|
2016-01-08 |
2017-07-13 |
Apg Therapeutics, Inc. |
Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
FI3411404T3
(fi)
|
2016-02-03 |
2023-01-31 |
|
T-soluja aktivoivia psma- ja cd3-bispesifisisiä vasta-ainekonstrukteja
|
MD3411402T2
(ro)
|
2016-02-03 |
2022-05-31 |
Amgen Res Munich Gmbh |
Constructe de anticorpi bispecifici BCMA și CD3 de angajare a celulei T
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
US11262359B2
(en)
|
2016-02-05 |
2022-03-01 |
NanoView Biosciences, Inc. |
Detection of exosomes having surface markers
|
US10465003B2
(en)
|
2016-02-05 |
2019-11-05 |
Janssen Biotech, Inc. |
Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
|
CN109196121B
(zh)
|
2016-02-29 |
2022-01-04 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
JP7023853B2
(ja)
|
2016-03-04 |
2022-02-22 |
アレクトル エルエルシー |
抗trem1抗体及びその使用方法
|
JP7157981B2
(ja)
|
2016-03-07 |
2022-10-21 |
チャールストンファーマ, エルエルシー |
抗ヌクレオリン抗体
|
WO2017156192A1
(en)
|
2016-03-08 |
2017-09-14 |
Academia Sinica |
Methods for modular synthesis of n-glycans and arrays thereof
|
TW202214700A
(zh)
|
2016-03-14 |
2022-04-16 |
日商中外製藥股份有限公司 |
用於癌之治療的細胞傷害誘導治療劑
|
CA3017776A1
(en)
|
2016-03-15 |
2017-09-21 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
LT3219727T
(lt)
|
2016-03-17 |
2021-02-10 |
Tillotts Pharma Ag |
Anti-tnf alfa antikūnai ir jų funkciniai fragmentai
|
CN109153718B
(zh)
|
2016-03-17 |
2022-02-08 |
努玛治疗有限公司 |
抗TNFα抗体及其功能片段
|
PL3219726T3
(pl)
|
2016-03-17 |
2021-07-19 |
Tillotts Pharma Ag |
Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty
|
WO2017158084A1
(en)
|
2016-03-17 |
2017-09-21 |
Numab Innovation Ag |
ANTI-TNFα-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
IL261261B2
(en)
|
2016-03-17 |
2024-04-01 |
Numab Therapeutics AG |
Antibodies against TNF-ALPHA and their functional fragments
|
US10745487B2
(en)
|
2016-03-22 |
2020-08-18 |
Bionomics Limited |
Method of treating cancer by administering an anti-LGR5 monoclonal antibody
|
EP3432924A1
(de)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Zellsekretierte minikörper und verwendungen davon
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
KR20180128471A
(ko)
|
2016-03-29 |
2018-12-03 |
얀센 바이오테크 인코포레이티드 |
항-il12 및/또는 항-il23 항체의 증가된 투여 간격을 사용한 건선의 치료
|
CA3019560A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
EP3443120A2
(de)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Verfahren zur überwachung und behandlung von krebs
|
JOP20170091B1
(ar)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
|
CN109379889A
(zh)
|
2016-04-22 |
2019-02-22 |
台湾浩鼎生技股份有限公司 |
通过经由globo系列抗原的免疫激活或免疫调节的癌症免疫疗法
|
KR20230124093A
(ko)
|
2016-05-10 |
2023-08-24 |
제넨테크, 인크. |
폴리펩타이드의 재조합 생산 동안 트리설파이드 결합을감소시키기 위한 방법
|
TWI794171B
(zh)
|
2016-05-11 |
2023-03-01 |
美商滬亞生物國際有限公司 |
Hdac抑制劑與pd-l1抑制劑之組合治療
|
WO2017194568A1
(en)
|
2016-05-11 |
2017-11-16 |
Sanofi |
Treatment regimen using anti-muc1 maytansinoid immunoconjugate antibody for the treatment of tumors
|
TWI808055B
(zh)
|
2016-05-11 |
2023-07-11 |
美商滬亞生物國際有限公司 |
Hdac 抑制劑與 pd-1 抑制劑之組合治療
|
ES2864150T3
(es)
|
2016-05-17 |
2021-10-13 |
Abbvie Biotherapeutics Inc |
Conjugados de fármacos con anticuerpos anti-cMet y métodos para su uso
|
CN109415441B
(zh)
|
2016-05-24 |
2023-04-07 |
英斯梅德股份有限公司 |
抗体及其制备方法
|
JP2019516748A
(ja)
|
2016-05-26 |
2019-06-20 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
がんを治療するためのpd−1/pd−l1阻害剤
|
KR20220028143A
(ko)
|
2016-05-27 |
2022-03-08 |
애브비 바이오테라퓨틱스 인크. |
항-cd40 항체 및 이의 용도
|
CA3024508A1
(en)
|
2016-05-27 |
2017-11-30 |
Agenus Inc. |
Anti-tim-3 antibodies and methods of use thereof
|
US10875921B2
(en)
|
2016-05-27 |
2020-12-29 |
Abbvie Biotherapeutics Inc. |
Anti-4-1BB antibodies and their uses
|
RU2764651C2
(ru)
|
2016-06-08 |
2022-01-19 |
Эббви Инк. |
Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
|
KR20190079713A
(ko)
|
2016-06-13 |
2019-07-05 |
아이-맵 |
항-pd-l1 항체 및 이것의 사용
|
EP3471767A4
(de)
|
2016-06-15 |
2020-01-15 |
Icahn School of Medicine at Mount Sinai |
Influenzavirus-hämagglutinin-proteine und verwendungen davon
|
CA3030099A1
(en)
|
2016-07-08 |
2018-01-11 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag |
新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
CN116082506A
(zh)
|
2016-07-22 |
2023-05-09 |
丹娜法伯癌症研究所公司 |
糖皮质激素诱导肿瘤坏死因子受体(gitr)抗体及其使用方法
|
KR102579850B1
(ko)
|
2016-07-22 |
2023-09-18 |
암젠 인크 |
Fc-함유 단백질의 정제 방법
|
EP3487880A1
(de)
|
2016-07-25 |
2019-05-29 |
Biogen MA Inc. |
Anti-hspa5(grp78)-antikörper und verwendungen davon
|
US11642400B2
(en)
|
2016-07-27 |
2023-05-09 |
Obi Pharma, Inc. |
Immunogenic/therapeutic glycan compositions and uses thereof
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
KR102528998B1
(ko)
|
2016-07-29 |
2023-05-03 |
오비아이 파머 인코퍼레이티드 |
인간 항체, 제약 조성물 및 방법
|
EP3490600A1
(de)
|
2016-08-01 |
2019-06-05 |
Xoma (Us) Llc |
Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
EP3496752B1
(de)
|
2016-08-12 |
2022-05-18 |
Genentech, Inc. |
Kombinationstherapie mit einem mek-inhibitor, einem pd-1-achsen-inhibitor und einem vegf-inhibitor
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
AU2017321973A1
(en)
|
2016-09-02 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
US20190233505A1
(en)
|
2016-09-06 |
2019-08-01 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating or preventing zika virus infection
|
EP3510046A4
(de)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
Antikörper gegen oxidationsspezifische epitope
|
WO2018049248A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus equipped with bispecific engager molecules
|
IL306104A
(en)
|
2016-09-14 |
2023-11-01 |
Abbvie Biotherapeutics Inc |
Antibodies against (CD27) PD-1
|
PT3328887T
(pt)
|
2016-09-19 |
2021-10-19 |
I Mab Biopharma Hangzhou Co Ltd |
Anticorpos anti-gm-csf e suas utilizações
|
EP3515478B1
(de)
|
2016-09-21 |
2024-02-28 |
Nextcure, Inc. |
Antikörper für siglec-15 und verfahren zur verwendung davon
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
MX2019003337A
(es)
|
2016-09-23 |
2019-09-26 |
Teva Pharmaceuticals Int Gmbh |
Tratamiento para migraña refractaria.
|
EP3518969A2
(de)
|
2016-09-28 |
2019-08-07 |
Xoma (Us) Llc |
Antikörper zur bindung von interleukin-2 und verwendungen davon
|
WO2018064299A1
(en)
|
2016-09-29 |
2018-04-05 |
Genentech, Inc. |
Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane
|
US20180106818A1
(en)
|
2016-10-03 |
2018-04-19 |
Abbott Laboratories |
Methods of assessing gfap status in patient samples
|
TWI775781B
(zh)
|
2016-10-06 |
2022-09-01 |
美商建南德克公司 |
癌症之治療性及診斷性方法
|
CN109843324A
(zh)
|
2016-10-06 |
2019-06-04 |
辉瑞公司 |
用于治疗癌症的avelumab用药方案
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
EP3526256A1
(de)
|
2016-10-11 |
2019-08-21 |
Agenus Inc. |
Anti-lag-3-antikörper und verfahren zur verwendung davon
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
JP7100030B2
(ja)
|
2016-10-28 |
2022-07-12 |
アスチュート メディカル,インコーポレイテッド |
腎機能の改善のためのtimp-2に対する抗体の使用
|
AU2017355402A1
(en)
|
2016-11-02 |
2019-05-30 |
Health Research, Inc. |
Combination treatment with antibody-drug conjugates and PARP inhibitors
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
AU2017353936A1
(en)
|
2016-11-04 |
2019-05-02 |
Novimmune Sa |
Anti-CD19 antibodies and methods of use thereof
|
KR102539159B1
(ko)
|
2016-11-07 |
2023-06-02 |
주식회사 뉴라클사이언스 |
서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
|
MX2019005552A
(es)
|
2016-11-14 |
2019-08-12 |
Amgen Inc |
Proteinas de union a antigenos biespecificas o biparatopicas y usos de las mismas.
|
US11401330B2
(en)
|
2016-11-17 |
2022-08-02 |
Seagen Inc. |
Glycan-interacting compounds and methods of use
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
TWI822055B
(zh)
|
2016-11-21 |
2023-11-11 |
台灣浩鼎生技股份有限公司 |
共軛生物分子、醫藥組成物及方法
|
CN110234319B
(zh)
|
2016-11-23 |
2022-09-27 |
转化药物开发有限责任公司 |
苯甲酰胺和活性化合物的组合物及其使用方法
|
BR112019008265A2
(pt)
|
2016-11-28 |
2019-07-09 |
Chugai Pharmaceutical Co Ltd |
molécula de ligação ao ligante cuja atividade de li-gação ao ligante é ajustável
|
KR20230037664A
(ko)
|
2016-12-07 |
2023-03-16 |
아게누스 인코포레이티드 |
항-ctla-4 항체 및 이의 사용 방법
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
ES2813057T3
(es)
|
2016-12-15 |
2021-03-22 |
Abbvie Biotherapeutics Inc |
Anticuerpos anti-ox40 y sus usos
|
CN110234659A
(zh)
|
2016-12-19 |
2019-09-13 |
特雷罗药物股份有限公司 |
用于敏感性分析的分析肽和方法
|
WO2018122043A1
(en)
|
2016-12-27 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
KR20210126136A
(ko)
|
2016-12-27 |
2021-10-19 |
에프. 호프만-라 로슈 아게 |
신규한 비오틴-특이적 단일클론 항체 및 그 용도
|
WO2018122204A1
(en)
|
2016-12-27 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Novel biotin-specific monoclonal antibody and use thereof
|
WO2018129284A1
(en)
|
2017-01-05 |
2018-07-12 |
The Johns Hopkins University |
Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
|
US20190315852A1
(en)
|
2017-01-05 |
2019-10-17 |
Netris Pharma |
Combined treatment with netrin-1 interfering drug and immune checkpoint inhibitors drugs
|
EP3567054A4
(de)
|
2017-01-06 |
2021-03-10 |
ABL Bio Inc. |
Anti-alpha-syn-antikörper und verwendung davon
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
MX2019007848A
(es)
|
2017-01-20 |
2019-09-09 |
Tayu Huaxia Biotech Medical Group Co Ltd |
Anticuerpos anti-pd-1 y usos de los mismos.
|
MY188386A
(en)
|
2017-01-24 |
2021-12-07 |
I Mab Biopharma Us Ltd |
Anti-cd73 antibodies and uses thereof
|
JP2020506916A
(ja)
|
2017-01-30 |
2020-03-05 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性乾癬性関節炎の治療のための抗tnf抗体、組成物、及び方法
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
CN110234995A
(zh)
|
2017-02-02 |
2019-09-13 |
豪夫迈·罗氏有限公司 |
使用至少两种聚乙二醇化的分析物特异性结合试剂的免疫测定
|
MA47442A
(fr)
|
2017-02-07 |
2019-12-18 |
Janssen Biotech Inc |
Anticorps anti-tnf, compositions et méthodes pour le traitement de la spondylarthrite ankylosante active
|
CN108456251A
(zh)
|
2017-02-21 |
2018-08-28 |
上海君实生物医药科技股份有限公司 |
抗pd-l1抗体及其应用
|
CN110546277A
(zh)
|
2017-03-01 |
2019-12-06 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
WO2018160909A1
(en)
|
2017-03-03 |
2018-09-07 |
Siamab Therapeutics, Inc. |
Glycan-interacting compounds and methods of use
|
TWI808963B
(zh)
|
2017-03-22 |
2023-07-21 |
法商賽諾菲公司 |
使用人類化抗cxcr5抗體治療狼瘡
|
US11016092B2
(en)
|
2017-03-23 |
2021-05-25 |
Abbott Laboratories |
Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase L1
|
WO2018174274A1
(ja)
|
2017-03-24 |
2018-09-27 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
ES2925227T3
(es)
|
2017-03-30 |
2022-10-14 |
Ecs Progastrin Sa |
Composiciones y procedimientos para detectar el cáncer de pulmón
|
WO2018178363A1
(en)
|
2017-03-30 |
2018-10-04 |
Progastrine Et Cancers S.À R.L. |
Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule
|
KR102644408B1
(ko)
|
2017-03-30 |
2024-03-07 |
메르크 파텐트 게엠베하 |
암의 치료를 위한 항-pd-l1 항체 및 dna-pk 억제제의 병용
|
JP7209298B2
(ja)
|
2017-03-31 |
2023-01-20 |
公立大学法人奈良県立医科大学 |
血液凝固第viii因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ix因子異常症の予防および/または治療に用いられる医薬組成物
|
US10722589B2
(en)
|
2017-04-03 |
2020-07-28 |
Covagen Ag |
FGFR3 binding molecules
|
JP7315466B2
(ja)
|
2017-04-05 |
2023-07-26 |
アスチュート メディカル,インコーポレイテッド |
生体試料中において改善した性能を有する、timp2に関するアッセイ
|
CA3058652A1
(en)
|
2017-04-07 |
2018-10-11 |
Icahn School Of Medicine At Mount Sinai |
Anti-influenza b virus neuraminidase antibodies and uses thereof
|
JOP20190243A1
(ar)
|
2017-04-12 |
2019-10-13 |
Medimmune Llc |
علاج الربو بجسم مضاد لـ tslp
|
CA3059366A1
(en)
|
2017-04-13 |
2018-10-18 |
Agenus Inc. |
Anti-cd137 antibodies and methods of use thereof
|
EP3610268A1
(de)
|
2017-04-15 |
2020-02-19 |
Abbott Laboratories |
Verfahren zur unterstützung bei der hyperakuten diagnose und bestimmung von traumatischen hirnverletzungen in einem menschlichen patienten mit frühbiomarkern
|
CA3059133A1
(en)
|
2017-04-21 |
2018-10-25 |
Staten Biotechnology B.V. |
Anti-apoc3 antibodies and methods of use thereof
|
BR112019022108A2
(pt)
|
2017-04-22 |
2020-05-12 |
Immunomic Therapeutics, Inc. |
Construções de lamp aprimoradas
|
JP7261739B2
(ja)
|
2017-04-27 |
2023-04-20 |
中外製薬株式会社 |
薬物動態が改善された血液凝固第ix因子
|
US20230140818A1
(en)
|
2017-04-27 |
2023-05-04 |
The University Of Hong Kong |
Use of hcn inhibitors for treatment of cancer
|
WO2018200823A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
ES2952961T3
(es)
|
2017-05-01 |
2023-11-07 |
Agenus Inc |
Anticuerpos anti-TIGIT y métodos de uso de los mismos
|
EP3618854A1
(de)
|
2017-05-02 |
2020-03-11 |
Immunomic Therapeutics, Inc. |
Lamp (lysosomale assoziierte membranprotein)-konstrukte mit krebsantigenen
|
EP3620531A4
(de)
|
2017-05-02 |
2021-03-17 |
National Center of Neurology and Psychiatry |
Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
|
US10865238B1
(en)
|
2017-05-05 |
2020-12-15 |
Duke University |
Complement factor H antibodies
|
EP3618864A1
(de)
|
2017-05-05 |
2020-03-11 |
Amgen Inc. |
Pharmazeutische zusammensetzung mit bispezifischen antikörperkonstrukten zur verbesserten aufbewahrung und verabreichung
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
WO2018213316A1
(en)
|
2017-05-16 |
2018-11-22 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
US10914729B2
(en)
|
2017-05-22 |
2021-02-09 |
The Trustees Of Princeton University |
Methods for detecting protein binding sequences and tagging nucleic acids
|
EP3630830A1
(de)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Neuer cd73-antikörper, herstellung und verwendungen davon
|
CN110651190A
(zh)
|
2017-05-25 |
2020-01-03 |
雅培实验室 |
用早期生物标记物帮助确定是否对已遭受或可能已遭受头部损伤的人受试者执行成像的方法
|
EP3630167A1
(de)
|
2017-05-26 |
2020-04-08 |
NovImmune SA |
Anti-cd47x-anti-mesothelin-antikörper und verfahren zu ihrer verwendung
|
EP3631467A1
(de)
|
2017-05-30 |
2020-04-08 |
Abbott Laboratories |
Verfahren zur hilfe bei der diagnose und evaluierung einer leichten traumatischen hirnläsion bei einer person unter verwendung von herztroponin i
|
US20200148768A1
(en)
|
2017-05-31 |
2020-05-14 |
Stcube & Co., Inc. |
Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof
|
AU2018277545A1
(en)
|
2017-05-31 |
2019-12-19 |
Stcube & Co., Inc. |
Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
EP3635007A1
(de)
|
2017-06-06 |
2020-04-15 |
STCube & Co., Inc. |
Verfahren zur behandlung von krebs unter verwendung von antikörpern und molekülen, die an btn1a1 oder btn1a1-liganden binden
|
PE20200013A1
(es)
|
2017-06-20 |
2020-01-06 |
Amgen Inc |
Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
|
WO2019000223A1
(en)
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
TW201920266A
(zh)
|
2017-07-14 |
2019-06-01 |
美商輝瑞大藥廠 |
Madcam 抗體
|
JP2020527351A
(ja)
|
2017-07-21 |
2020-09-10 |
ジェネンテック, インコーポレイテッド |
がんの治療法及び診断法
|
CN111491661A
(zh)
|
2017-07-27 |
2020-08-04 |
诺莫坎制药有限责任公司 |
M(h)dm2/4的抗体及其在诊断和治疗癌症中的用途
|
EP4248996A3
(de)
|
2017-08-03 |
2023-11-08 |
Alector LLC |
Anti-trem2 antikörper und deren verwendung
|
KR20200033798A
(ko)
|
2017-08-03 |
2020-03-30 |
알렉터 엘엘씨 |
항-cd33 항체 및 이의 이용 방법
|
MX2020001327A
(es)
|
2017-08-04 |
2020-03-20 |
Amgen Inc |
Metodo de conjugacion de cys-acm.
|
WO2019036842A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
DYNAMIC LIBRARIES OF HUMAN HEAVY CHAIN ANTIBODIES
|
KR20200054209A
(ko)
|
2017-08-21 |
2020-05-19 |
아다진 인크. |
동적 인간 항체 경쇄 라이브러리
|
MX2020002612A
(es)
|
2017-09-07 |
2020-07-13 |
Univ Res Inst Inc Augusta |
Anticuerpos de la proteina de muerte celular programada 1.
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
BR112020005737A2
(pt)
|
2017-09-22 |
2020-11-17 |
F. Hoffmann-La Roche Ag |
anticorpo recombinante multivalente e uso do mesmo, kit e método para detectar um antígeno
|
TW201922780A
(zh)
*
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
EP3694890A4
(de)
|
2017-10-12 |
2021-11-03 |
Immunowake Inc. |
Leichtkettiges antikörperfusionsprotein mit vegfr
|
US11692037B2
(en)
|
2017-10-20 |
2023-07-04 |
Hyogo College Of Medicine |
Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
|
US11826414B2
(en)
|
2017-10-23 |
2023-11-28 |
Cz Biohub Sf, Llc |
Measurement of afucosylated IgG Fc glycans and related vaccination methods
|
WO2019084460A1
(en)
|
2017-10-26 |
2019-05-02 |
The Regents Of The University Of California |
INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY
|
AU2018361957B2
(en)
|
2017-10-31 |
2023-05-25 |
Staten Biotechnology B.V. |
Anti-ApoC3 antibodies and methods of use thereof
|
US20190160089A1
(en)
|
2017-10-31 |
2019-05-30 |
Immunogen, Inc. |
Combination treatment with antibody-drug conjugates and cytarabine
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
EP3717069A1
(de)
|
2017-11-27 |
2020-10-07 |
Purdue Pharma L.P. |
Gegen menschlichen gewebefaktor gerichtete humanisierte antikörper
|
EP3719036A4
(de)
|
2017-11-28 |
2021-09-08 |
Chugai Seiyaku Kabushiki Kaisha |
Ligandbindendes molekül mit einstellbarer ligandbindungsaktivität
|
MX2020005424A
(es)
|
2017-11-29 |
2020-12-03 |
Univ Texas |
Composiciones y metodos para terapia contra el cancer.
|
ES2920283T3
(es)
|
2017-12-05 |
2022-08-02 |
Progastrine Et Cancers S A R L |
Terapia de combinación entre un anticuerpo antiprogastrina y la inmunoterapia para tratar el cáncer
|
WO2019113375A2
(en)
|
2017-12-06 |
2019-06-13 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
EP3721234A1
(de)
|
2017-12-09 |
2020-10-14 |
Abbott Laboratories |
Verfahren zur unterstützung bei der diagnose und bewertung einer traumatischen hirnverletzung beim menschen mit einer kombination aus gfap und uch-l1
|
WO2019113525A2
(en)
|
2017-12-09 |
2019-06-13 |
Abbott Laboratories |
Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)
|
SG11202004273YA
(en)
|
2017-12-11 |
2020-06-29 |
Amgen Inc |
Continuous manufacturing process for bispecific antibody products
|
EP3710484B1
(de)
|
2017-12-20 |
2023-10-25 |
Harbour Biomed (Shanghai) Co., Ltd |
Ctla-4-bindende antikörper und verwendungen davon
|
WO2019133902A2
(en)
|
2017-12-28 |
2019-07-04 |
Astute Medical, Inc. |
Antibodies and assays for ccl14
|
US20220135687A1
(en)
|
2017-12-28 |
2022-05-05 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
EP3732202A4
(de)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
Einzeldomänenantikörper und varianten davon gegen tigit
|
US11667713B2
(en)
|
2017-12-28 |
2023-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
TW201940518A
(zh)
|
2017-12-29 |
2019-10-16 |
美商安進公司 |
針對muc17和cd3之雙特異性抗體構建體
|
AR114080A1
(es)
|
2018-01-12 |
2020-07-22 |
Amgen Inc |
Anticuerpos pac1 y sus usos
|
KR20200108868A
(ko)
|
2018-01-12 |
2020-09-21 |
브리스톨-마이어스 스큅 컴퍼니 |
암을 치료하기 위한 항-il-8 항체 및 항-pd-1 항체와의 조합 요법
|
CA3084518A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
US20210251899A1
(en)
|
2018-01-25 |
2021-08-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
|
WO2019145537A1
(en)
|
2018-01-26 |
2019-08-01 |
Ecs-Progastrin Sa |
Combination of progastrin detection with other cancer biomarkers in cancer diagnosis
|
WO2019151418A1
(ja)
|
2018-01-31 |
2019-08-08 |
元一 加藤 |
Il-6阻害剤を含有する喘息の治療剤
|
TW202000702A
(zh)
|
2018-02-26 |
2020-01-01 |
美商建南德克公司 |
用於抗tigit拮抗劑抗體及抗pd-l1拮抗劑抗體治療之投藥
|
US20200400675A1
(en)
|
2018-02-27 |
2020-12-24 |
Ecs-Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
WO2019169229A1
(en)
|
2018-03-01 |
2019-09-06 |
Nextcure, Inc. |
Klrg1 binding compositions and methods of use thereof
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
BR112020017701A2
(pt)
|
2018-03-12 |
2020-12-29 |
Zoetis Services Llc |
Anticorpos anti-ngf e métodos dos mesmos
|
AU2019235033A1
(en)
|
2018-03-14 |
2020-07-30 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
US11203646B2
(en)
|
2018-03-14 |
2021-12-21 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
CN112040979A
(zh)
|
2018-03-21 |
2020-12-04 |
Alx肿瘤生物技术公司 |
针对信号调控蛋白α的抗体和使用方法
|
WO2019180272A1
(en)
|
2018-03-23 |
2019-09-26 |
Fundación Instituto De Investigación Sanitaria De Santiago De Compostela |
Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases
|
CA3093850A1
(en)
*
|
2018-03-26 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents for testing therapeutic agents
|
PL3775909T3
(pl)
|
2018-03-26 |
2023-09-18 |
Glycanostics S.R.O. |
Środki i sposoby do profilowania glikozylacji białka
|
PE20201343A1
(es)
|
2018-04-02 |
2020-11-25 |
Bristol Myers Squibb Co |
Anticuerpos anti-trem-1 y usos de los mismos
|
WO2019197651A1
(en)
|
2018-04-12 |
2019-10-17 |
Mediapharma S.R.L. |
Lgals3bp antibody-drug-conjugate and its use for the treatment of cancer
|
EP3784274A1
(de)
|
2018-04-27 |
2021-03-03 |
Fondazione Ebri Rita Levi-Montalcini |
Gegen ein tau-abgeleitetes neurotoxisches peptid gerichteter antikörper und verwendungen davon
|
JP2021522298A
(ja)
|
2018-05-04 |
2021-08-30 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
癌治療のためのPD−1/PD−L1、TGFβおよびDNA−PKの同時阻害
|
CA3100004A1
(en)
|
2018-05-15 |
2019-11-21 |
Immunomic Therapeutics, Inc. |
Improved lamp constructs comprising allergens
|
TW202003048A
(zh)
|
2018-05-15 |
2020-01-16 |
美商伊繆諾金公司 |
用抗體-藥物偶聯物及flt3抑制劑之組合治療
|
WO2019220412A2
(en)
|
2018-05-18 |
2019-11-21 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
JPWO2019225568A1
(ja)
|
2018-05-21 |
2021-07-01 |
中外製薬株式会社 |
ガラス容器に封入された凍結乾燥製剤
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
US11319373B2
(en)
|
2018-05-25 |
2022-05-03 |
Alector Llc |
Anti-SIRPA antibodies and methods of use thereof
|
WO2019232321A1
(en)
|
2018-06-01 |
2019-12-05 |
NanoView Biosciences, Inc. |
Compositions, systems, and methods for enhanced label-free and fluorescence - based detection of nanoparticles
|
EP3802610A1
(de)
|
2018-06-05 |
2021-04-14 |
Amgen Inc. |
Modulation von körperabhängiger zellphagozytose
|
AU2019282778A1
(en)
|
2018-06-08 |
2020-12-10 |
Alector Llc |
Anti-Siglec-7 antibodies and methods of use thereof
|
AU2019288677A1
(en)
|
2018-06-21 |
2021-01-14 |
Yumanity Therapeutics, Inc. |
Compositions and methods for the treatment and prevention of neurological disorders
|
WO2019246557A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020006176A1
(en)
|
2018-06-27 |
2020-01-02 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
WO2020003210A1
(en)
|
2018-06-29 |
2020-01-02 |
Kangwon National University University-Industry Cooperation Foundation |
Anti-l1cam antibodies and uses thereof
|
FI3618928T3
(fi)
|
2018-07-13 |
2023-04-21 |
Alector Llc |
Anti-sortiliini-vasta-aineita ja menetelmiä niiden käyttämiseksi
|
KR20210034622A
(ko)
|
2018-07-18 |
2021-03-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 항 대사제, 및 백금 제제를 이용한 폐암 치료 방법
|
BR112021000934A2
(pt)
|
2018-07-20 |
2021-04-27 |
Pierre Fabre Medicament |
receptor para vista
|
MX2021000933A
(es)
|
2018-07-27 |
2021-05-27 |
Alector Llc |
Anticuerpos anti-siglec-5 y métodos para su uso.
|
CN112771075A
(zh)
|
2018-07-30 |
2021-05-07 |
安进研发(慕尼黑)股份有限公司 |
结合至cd33和cd3的双特异性抗体构建体的延长施用
|
EA202190435A1
(ru)
|
2018-08-03 |
2021-06-30 |
Эмджен Рисерч (Мюник) Гмбх |
Конструкции на основе антител для связывания cldn18.2 и cd3
|
AU2019319822A1
(en)
|
2018-08-08 |
2021-03-18 |
Genentech, Inc. |
Use of tryptophan derivatives and L-methionine for protein formulation
|
WO2020043670A1
(en)
|
2018-08-27 |
2020-03-05 |
Affimed Gmbh |
Cryopreserved nk cells preloaded with an antibody construct
|
CA3110530A1
(en)
|
2018-09-11 |
2020-03-19 |
Amgen Inc. |
Methods of modulating antibody-dependent cell-mediated cytotoxicity
|
WO2020053325A1
(en)
|
2018-09-12 |
2020-03-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
AU2019342099A1
(en)
|
2018-09-19 |
2021-04-08 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
EP4249917A3
(de)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnosemethoden für dreifach-negativen brustkrebs
|
CN113164596A
(zh)
|
2018-09-24 |
2021-07-23 |
詹森生物科技公司 |
用抗il12/il23抗体治疗溃疡性结肠炎的安全且有效的方法
|
CA3114024A1
(en)
|
2018-09-26 |
2020-04-02 |
Merck Patent Gmbh |
Combination of a pd-1 antagonist, an atr inhibitor and a platinating agent for the treatment of cancer
|
KR20210068408A
(ko)
|
2018-09-28 |
2021-06-09 |
암젠 인크 |
가용성 bcma에 대한 항체
|
AU2019352017A1
(en)
|
2018-10-03 |
2021-05-06 |
Staten Biotechnology B.V. |
Antibodies specific for human and cynomolgus ApoC3 and methods of use thereof
|
US11130802B2
(en)
|
2018-10-10 |
2021-09-28 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants
|
WO2020077212A1
(en)
|
2018-10-11 |
2020-04-16 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
CA3116234A1
(en)
|
2018-10-15 |
2020-04-23 |
Merck Patent Gmbh |
Combination therapy utilizing dna alkylating agents and atr inhibitors
|
CN113196061A
(zh)
|
2018-10-18 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
肉瘤样肾癌的诊断和治疗方法
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
CA3118453A1
(en)
|
2018-11-02 |
2020-05-07 |
The Regents Of The University Of California |
Compositions and methods for treating brain injury
|
EP3877407A1
(de)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von zwei kettenproteinen in prokaryotischen wirtszellen
|
US20220011301A1
(en)
|
2018-11-16 |
2022-01-13 |
Roche Diagnostics Operations, Inc. |
Streptavidin-coated solid phases with a member of a binding pair
|
CA3119807A1
(en)
|
2018-12-04 |
2020-06-11 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
|
US20220098310A1
(en)
|
2018-12-06 |
2022-03-31 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
US20220026445A1
(en)
|
2018-12-07 |
2022-01-27 |
Georgia Tech Research Corporation |
Antibodies that bind to natively folded myocilin
|
CN115120716A
(zh)
|
2019-01-14 |
2022-09-30 |
健泰科生物技术公司 |
用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
|
AU2020211976A1
(en)
|
2019-01-23 |
2021-07-15 |
Genentech, Inc. |
Methods of producing multimeric proteins in eukaryotic host cells
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
WO2020157122A1
(en)
|
2019-01-29 |
2020-08-06 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Treating the causative agent in adhesiogenesis
|
AU2019427766A1
(en)
|
2019-01-30 |
2021-09-16 |
Nomocan Pharmaceuticals Llc |
Antibodies to M(H)DM2/4 and their use in diagnosing and treating cancer
|
WO2020163589A1
(en)
|
2019-02-08 |
2020-08-13 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
US11028176B2
(en)
|
2019-02-13 |
2021-06-08 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
CN112703013B
(zh)
|
2019-02-22 |
2022-09-30 |
武汉友芝友生物制药股份有限公司 |
Cd3抗原结合片段及其应用
|
US11242407B2
(en)
|
2019-02-26 |
2022-02-08 |
Inspirna, Inc. |
High-affinity anti-MERTK antibodies and uses thereof
|
CA3130695A1
(en)
|
2019-02-27 |
2020-09-03 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
|
CN113508140A
(zh)
|
2019-02-28 |
2021-10-15 |
学校法人顺天堂 |
与切断型的突变型Calreticulin结合的抗体以及骨髄增殖性肿瘤的诊断、预防或治疗药
|
KR20230146132A
(ko)
|
2019-03-15 |
2023-10-18 |
카티전 테라퓨틱스, 인코포레이티드 |
항-bcma 키메라 항원 수용체
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
JP2022525149A
(ja)
|
2019-03-20 |
2022-05-11 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
ベネトクラクスが失敗した急性骨髄性白血病(aml)の処置
|
US11090336B2
(en)
|
2019-03-27 |
2021-08-17 |
The Trustees Of The University Of Pennsylvania |
Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
|
CN113874392A
(zh)
|
2019-03-28 |
2021-12-31 |
丹尼斯科美国公司 |
工程化抗体
|
JPWO2020209318A1
(de)
|
2019-04-10 |
2020-10-15 |
|
|
CA3135694A1
(en)
|
2019-04-17 |
2020-10-22 |
Hiroshima University |
Therapeutic agent for urological cancer which is characterized by being administered with il-6 inhibitor and ccr2 inhibitor in combination
|
US20230135930A1
(en)
|
2019-04-24 |
2023-05-04 |
Heidelberg Pharma Research Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
CN114269376A
(zh)
|
2019-05-03 |
2022-04-01 |
豪夫迈·罗氏有限公司 |
用抗pd-l1抗体治疗癌症的方法
|
US20200369759A1
(en)
|
2019-05-23 |
2020-11-26 |
Fibrogen, Inc. |
Methods of treatment of muscular dystrophies
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
CN114174344A
(zh)
|
2019-05-30 |
2022-03-11 |
美国安进公司 |
工程改造铰链区以驱动抗体二聚化
|
BR112021023735A2
(pt)
|
2019-06-05 |
2022-01-04 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação de sítio de clivagem de anti-corpo
|
EP3983520A1
(de)
|
2019-06-13 |
2022-04-20 |
Amgen, Inc |
Automatisierte biomassebasierte perfusionssteuerung zur herstellung von biologika
|
AU2020304671A1
(en)
|
2019-06-28 |
2022-01-20 |
Amgen Inc. |
Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
|
CN114585644A
(zh)
|
2019-08-30 |
2022-06-03 |
艾吉纳斯公司 |
抗cd96抗体及其使用方法
|
US20220348650A1
(en)
|
2019-09-03 |
2022-11-03 |
Bio-Thera Solutions, Ltd. |
Anti-tigit immunosuppressant and application thereof
|
CR20220095A
(es)
|
2019-09-04 |
2022-06-06 |
Genentech Inc |
Agentes de unión a cd8 y usos de los mismos
|
EP4028416A1
(de)
|
2019-09-10 |
2022-07-20 |
Amgen Inc. |
Reinigungsverfahren für bispezifische antigen-bindende polypeptide mit erhöhter dynamischer bindungskapazität beim protein-l-einfang
|
CN114340675A
(zh)
|
2019-09-12 |
2022-04-12 |
豪夫迈·罗氏有限公司 |
治疗狼疮性肾炎的组合物和方法
|
WO2021062323A1
(en)
|
2019-09-26 |
2021-04-01 |
Stcube & Co. |
Antibodies specific to glycosylated ctla-4 and methods of use thereof
|
MX2022003610A
(es)
|
2019-09-27 |
2022-04-20 |
Genentech Inc |
Administracion de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1.
|
CN114829404A
(zh)
|
2019-10-09 |
2022-07-29 |
斯特库比公司 |
对糖基化的lag3特异的抗体及其使用方法
|
JP2022551732A
(ja)
|
2019-10-18 |
2022-12-13 |
イミュノミック セラピューティックス, インコーポレイテッド |
がん抗原を含む改良lamp構築物
|
WO2021076930A1
(en)
|
2019-10-18 |
2021-04-22 |
The Regents Of The University Of California |
Plxdc activators and their use in the treatment of blood vessel disorders
|
KR20220095205A
(ko)
|
2019-11-01 |
2022-07-06 |
아레스 트레이딩 에스.아. |
암의 치료를 위한 방사선요법과 PD-1, TGFβ 및 ATM의 조합 억제
|
US20220401481A1
(en)
|
2019-11-01 |
2022-12-22 |
Magenta Therapeutics, Inc. |
Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
|
AU2020379201A1
(en)
|
2019-11-05 |
2022-05-26 |
Glaxosmithkline Intellectual Property (No. 4) Ltd. |
Combined inhibition of PD-1, TGFβ and TIGIT for the treatment of cancer
|
KR20220092580A
(ko)
|
2019-11-06 |
2022-07-01 |
제넨테크, 인크. |
혈액암의 치료를 위한 진단과 치료 방법
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
EP4058485A1
(de)
|
2019-11-13 |
2022-09-21 |
Amgen Inc. |
Verfahren zur verringerung der aggregatbildung bei der nachgelagerten verarbeitung von bispezifischen antigen-bindenden molekülen
|
JP2023501717A
(ja)
|
2019-11-19 |
2023-01-18 |
アムジエン・インコーポレーテツド |
新規の多重特異性抗体フォーマット
|
EP3825330A1
(de)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117-antikörper und verfahren zur verwendung davon
|
WO2021113655A1
(en)
|
2019-12-05 |
2021-06-10 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
US11897950B2
(en)
|
2019-12-06 |
2024-02-13 |
Augusta University Research Institute, Inc. |
Osteopontin monoclonal antibodies
|
CR20220322A
(es)
|
2019-12-09 |
2022-07-28 |
Genentech Inc |
Formulaciones de anticuerpos anti-pd-l1
|
BR112022011337A2
(pt)
|
2019-12-12 |
2022-08-23 |
Alector Llc |
Método para tratar e/ou retardar a progressão de uma doença ou lesão em um indivíduo
|
WO2021127528A1
(en)
|
2019-12-20 |
2021-06-24 |
Amgen Inc. |
Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors
|
WO2021130383A1
(en)
|
2019-12-27 |
2021-07-01 |
Affimed Gmbh |
Method for the production of bispecific fcyriii x cd30 antibody construct
|
CN115052663A
(zh)
|
2020-01-08 |
2022-09-13 |
辛瑟斯治疗股份有限公司 |
Alk5抑制剂缀合物及其用途
|
EP4093771A1
(de)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Kombinationen von antikörperkonstrukten und inhibitoren des zytokinfreisetzungssyndroms und verwendungen davon
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
JP2023512654A
(ja)
|
2020-01-31 |
2023-03-28 |
ジェネンテック, インコーポレイテッド |
Pd-1軸結合アンタゴニストおよびrnaワクチンを用いてネオエピトープ特異的t細胞を誘導する方法
|
CN113248611A
(zh)
|
2020-02-13 |
2021-08-13 |
湖南华康恒健生物技术有限公司 |
抗bcma抗体、其药物组合物及应用
|
US20230159637A1
(en)
|
2020-02-24 |
2023-05-25 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
CA3174103A1
(en)
|
2020-03-06 |
2021-09-10 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
US11896619B2
(en)
|
2020-03-10 |
2024-02-13 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of NPM1c-positive cancer
|
WO2021183861A1
(en)
|
2020-03-12 |
2021-09-16 |
Amgen Inc. |
Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
|
EP4121459A1
(de)
|
2020-03-19 |
2023-01-25 |
Amgen Inc. |
Antikörper gegen mucin 17 und verwendungen davon
|
WO2021193928A1
(ja)
|
2020-03-27 |
2021-09-30 |
株式会社PhotoQ3 |
腫瘍細胞を死滅させるための医薬
|
US20230203191A1
(en)
|
2020-03-30 |
2023-06-29 |
Danisco Us Inc |
Engineered antibodies
|
EP4130035A1
(de)
|
2020-03-31 |
2023-02-08 |
Bio-Thera Solutions, Ltd. |
Antikörper und fusionsprotein zur behandlung von coronaviren und verwendung davon
|
CA3172451A1
(en)
|
2020-04-03 |
2021-10-07 |
Robert Paul |
Methods of use of anti-trem2 antibodies
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN115379858A
(zh)
|
2020-04-06 |
2022-11-22 |
光爱科技公司 |
用于杀死肿瘤细胞的医药品
|
EP4132971A1
(de)
|
2020-04-09 |
2023-02-15 |
Merck Sharp & Dohme LLC |
Affinitätsgereifte anti-lap-antikörper und verwendungen davon
|
WO2021211331A1
(en)
|
2020-04-13 |
2021-10-21 |
Abbott Point Of Care Inc. |
METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE
|
WO2021209458A1
(en)
|
2020-04-14 |
2021-10-21 |
Ares Trading S.A. |
Combination treatment of cancer
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
CN115997009A
(zh)
|
2020-04-27 |
2023-04-21 |
美真达治疗公司 |
用于在体内转导造血干细胞和祖细胞的方法和组合物
|
JP2023523145A
(ja)
|
2020-04-27 |
2023-06-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
リポ蛋白(a)に対するイソ型非依存性抗体
|
EP4143345A1
(de)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Verfahren und zusammensetzungen zur immuntherapie gegen nicht-kleinzelligen lungenkrebs
|
JP2023527293A
(ja)
|
2020-05-19 |
2023-06-28 |
アムジエン・インコーポレーテツド |
Mageb2結合構築物
|
CN115667515A
(zh)
|
2020-05-22 |
2023-01-31 |
中外制药株式会社 |
中和具有凝血因子viii(f.viii)功能替代活性的物质的抗体
|
EP3915641A1
(de)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5-antikörper und verfahren zu ihrer verwendung
|
EP4157874A2
(de)
|
2020-05-29 |
2023-04-05 |
Amgen Inc. |
Die nebenwirkungen mindernde verabreichung eines bispezifischen antikörperkonstrukts, das an cd33 und cd3 bindet
|
US20230235080A1
(en)
|
2020-06-03 |
2023-07-27 |
Bionecure Therapeutics, Inc. |
Trophoblast cell-surface antigen-2 (trop-2) antibodies
|
WO2021249969A1
(en)
|
2020-06-10 |
2021-12-16 |
Merck Patent Gmbh |
Combination product for the treatment of cancer diseases
|
WO2021257503A1
(en)
|
2020-06-16 |
2021-12-23 |
Genentech, Inc. |
Methods and compositions for treating triple-negative breast cancer
|
MX2022015881A
(es)
|
2020-06-18 |
2023-01-24 |
Genentech Inc |
Tratamiento con anticuerpos anti-tigit y antagonistas de union al eje de pd-1.
|
WO2021261546A1
(ja)
|
2020-06-24 |
2021-12-30 |
国立大学法人 東京大学 |
光増感色素
|
WO2022006562A1
(en)
|
2020-07-03 |
2022-01-06 |
Dana-Farber Cancer Institute, Inc. |
Multispecific coronavirus antibodies
|
US20230322867A1
(en)
|
2020-07-24 |
2023-10-12 |
Amgen Inc. |
Immunogens derived from sars-cov2 spike protein
|
WO2022025030A1
(ja)
|
2020-07-28 |
2022-02-03 |
中外製薬株式会社 |
新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
|
AU2021317974A1
(en)
|
2020-07-31 |
2023-03-16 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical Composition comprising Cell Expressing Chimeric Receptor
|
CA3190109A1
(en)
|
2020-07-31 |
2022-02-03 |
Genentech, Inc. |
Anti-integrin beta7 antibody formulations and devices
|
WO2022031749A1
(en)
|
2020-08-03 |
2022-02-10 |
Genentech, Inc. |
Diagnostic and therapeutic methods for lymphoma
|
EP4193149A1
(de)
|
2020-08-04 |
2023-06-14 |
Abbott Laboratories |
Verbesserte verfahren und kits zum nachweis von sars-cov-2-protein in einer probe
|
CN114057877A
(zh)
|
2020-08-07 |
2022-02-18 |
百奥泰生物制药股份有限公司 |
抗pd-l1抗体及其应用
|
EP4196612A1
(de)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostische und therapeutische verfahren für krebs
|
CA3191710A1
(en)
|
2020-08-20 |
2022-02-24 |
Amgen Inc. |
Antigen binding proteins with non-canonical disulfide in fab region
|
CN114106173A
(zh)
|
2020-08-26 |
2022-03-01 |
上海泰槿生物技术有限公司 |
抗ox40抗体、其药物组合物及应用
|
US20240092890A1
(en)
|
2020-08-27 |
2024-03-21 |
Juntendo Educational Foundation |
Anti-cleaved mutant calr-cd3 bispecific antibody and pharmaceutical composition
|
WO2022047381A1
(en)
|
2020-08-31 |
2022-03-03 |
Genentech, Inc. |
Methods for producing antibodies
|
CN116390750A
(zh)
|
2020-09-04 |
2023-07-04 |
罗格斯新泽西州立大学 |
SARS-CoV-2疫苗和抗体
|
JP2023541456A
(ja)
|
2020-09-14 |
2023-10-02 |
ブイオーアール バイオファーマ インコーポレーテッド |
がん治療用キメラ抗原受容体
|
EP4225786A2
(de)
|
2020-10-07 |
2023-08-16 |
Amgen Inc. |
Rationale auswahl von bausteinen zur anordnung multispezifischer antikörper
|
CA3187272A1
(en)
|
2020-10-08 |
2022-04-14 |
Thorsten Ross |
Trispecific binders
|
US20230382978A1
(en)
|
2020-10-15 |
2023-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
WO2022090455A1
(en)
|
2020-11-02 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
Sars-cov-2 nucleocapsid antibodies
|
JP2023550900A
(ja)
|
2020-11-02 |
2023-12-06 |
アレス トレーディング ソシエテ アノニム |
がんの組み合わせ治療
|
AU2021372815A1
(en)
|
2020-11-02 |
2023-06-22 |
Ares Trading S.A. |
Combination treatment of cancer
|
AU2021375733A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
WO2022096700A1
(en)
|
2020-11-06 |
2022-05-12 |
Amgen Research (Munich) Gmbh |
Polypeptide constructs selectively binding to cldn6 and cd3
|
MX2023005197A
(es)
|
2020-11-06 |
2023-05-16 |
Amgen Inc |
Dominio de union a antigeno con tasa de recorte reducida.
|
WO2022095970A1
(zh)
|
2020-11-06 |
2022-05-12 |
百奥泰生物制药股份有限公司 |
双特异抗体及其应用
|
CN116323671A
(zh)
|
2020-11-06 |
2023-06-23 |
安进公司 |
具有增加的选择性的多靶向性双特异性抗原结合分子
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
WO2022100694A1
(zh)
|
2020-11-12 |
2022-05-19 |
迈威(上海)生物科技股份有限公司 |
抗体及其制备方法
|
CA3198161A1
(en)
|
2020-12-01 |
2022-06-09 |
Beth MCQUISTON |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
AR124681A1
(es)
|
2021-01-20 |
2023-04-26 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
AU2022232951A1
(en)
|
2021-03-10 |
2023-10-19 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
CA3211328A1
(en)
|
2021-03-12 |
2022-09-15 |
Takatoshi Ozawa |
Pharmaceutical composition for treatment or prevention of myasthenia gravis
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP4308694A1
(de)
|
2021-03-16 |
2024-01-24 |
Magenta Therapeutics, Inc. |
Dosierschemata zur mobilisierung hämatopoetischer stammzellen für stammzelltransplantationen bei patienten mit multiplem myelom
|
JP2024511137A
(ja)
|
2021-03-22 |
2024-03-12 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
AU2022241935A1
(en)
|
2021-03-22 |
2023-09-28 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
AR125290A1
(es)
|
2021-04-02 |
2023-07-05 |
Amgen Inc |
Construcciones de unión a mageb2
|
JP2024514530A
(ja)
|
2021-04-02 |
2024-04-02 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
切断型cdcp1に対する抗体およびその使用
|
EP4319728A1
(de)
|
2021-04-09 |
2024-02-14 |
Genentech, Inc. |
Kombinationstherapie mit einem raf-hemmer und einem pd-1-achsen-hemmer
|
WO2022218957A1
(en)
|
2021-04-12 |
2022-10-20 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
WO2022225921A1
(en)
|
2021-04-20 |
2022-10-27 |
Amgen Inc. |
Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly
|
EP4330281A1
(de)
|
2021-04-29 |
2024-03-06 |
Amgen Inc. |
Verfahren zur reduzierung von spezies mit niedrigem molekulargewicht von rekombinant hergestellten proteinen
|
CA3218697A1
(en)
|
2021-05-03 |
2022-11-10 |
Merck Patent Gmbh |
Her2 targeting fc antigen binding fragment-drug conjugates
|
EP4334353A1
(de)
|
2021-05-04 |
2024-03-13 |
Regeneron Pharmaceuticals, Inc. |
Multispezifische fgf21-rezeptoragonisten und deren verwendungen
|
WO2022234102A1
(en)
|
2021-05-06 |
2022-11-10 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
EP4334354A1
(de)
|
2021-05-06 |
2024-03-13 |
Dana-Farber Cancer Institute, Inc. |
Antikörper gegen alk und verfahren zur verwendung davon
|
WO2022245920A1
(en)
|
2021-05-18 |
2022-11-24 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
EP4346905A1
(de)
|
2021-05-25 |
2024-04-10 |
Merck Patent GmbH |
Egfr-zielgerichtete fc-antigen-bindende fragment-arzneimittelkonjugate
|
EP4351640A1
(de)
|
2021-06-07 |
2024-04-17 |
Ares Trading S.A. |
Kombinationsbehandlung von krebs
|
CA3218481A1
(en)
|
2021-06-14 |
2022-12-22 |
argenx BV |
Anti-il-9 antibodies and methods of use thereof
|
CA3222291A1
(en)
|
2021-06-14 |
2022-12-22 |
Jaime MARINO |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2023010118A1
(en)
|
2021-07-29 |
2023-02-02 |
Vor Biopharma Inc. |
Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same
|
IL308154A
(en)
|
2021-07-30 |
2023-12-01 |
Affimed Gmbh |
Double structure antibodies
|
WO2023014863A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
IL310535A
(en)
|
2021-08-10 |
2024-03-01 |
Byomass Inc |
Anti-GDF15 antibodies, compositions and uses thereof
|
WO2023023491A1
(en)
|
2021-08-16 |
2023-02-23 |
Hemogenyx Pharmaceuticals Llc |
Anti-flt3 antibodies, cars, car t cells and methods of use
|
AU2022328625A1
(en)
|
2021-08-17 |
2024-03-21 |
Eli Lilly And Company |
Bispecific anti-flt3/cd3 antibodies and methods of use
|
CA3230038A1
(en)
|
2021-08-31 |
2023-03-09 |
Hongwei Zhang |
Methods and systems of diagnosing brain injury
|
WO2023034569A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
TW202325733A
(zh)
|
2021-09-03 |
2023-07-01 |
美商Go治療公司 |
抗醣化-lamp1抗體及其用途
|
WO2023056268A1
(en)
|
2021-09-30 |
2023-04-06 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
WO2023057871A1
(en)
|
2021-10-04 |
2023-04-13 |
Novartis Ag |
Surfactant stabilizers
|
WO2023058705A1
(ja)
|
2021-10-08 |
2023-04-13 |
中外製薬株式会社 |
抗hla-dq2.5抗体の製剤
|
WO2023069421A1
(en)
|
2021-10-18 |
2023-04-27 |
Byomass Inc. |
Anti-activin a antibodies, compositions and uses thereof
|
WO2023072904A1
(en)
|
2021-10-26 |
2023-05-04 |
F. Hoffmann-La Roche Ag |
Monoclonal antibodies specific for sars-cov-2 rbd
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023078968A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023081471A1
(en)
|
2021-11-05 |
2023-05-11 |
Dana-Farber Cancer Institute, Inc. |
Human broadly crossreactive influenza monoclonal antibodies and methods of use thereof
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023097024A1
(en)
|
2021-11-24 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against ctla-4 and methods of use thereof
|
WO2023114544A1
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies and uses thereof
|
WO2023111168A1
(en)
|
2021-12-17 |
2023-06-22 |
F. Hoffmann-La Roche Ag |
A novel antibody for detection of amyloid beta 42 (aβ42)
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
WO2023114543A2
(en)
|
2021-12-17 |
2023-06-22 |
Dana-Farber Cancer Institute, Inc. |
Platform for antibody discovery
|
WO2023122213A1
(en)
|
2021-12-22 |
2023-06-29 |
Byomass Inc. |
Targeting gdf15-gfral pathway cross-reference to related applications
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023147107A1
(en)
|
2022-01-31 |
2023-08-03 |
Byomass Inc. |
Myeloproliferative conditions
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023164516A1
(en)
|
2022-02-23 |
2023-08-31 |
Alector Llc |
Methods of use of anti-trem2 antibodies
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
EP4245772A1
(de)
|
2022-03-18 |
2023-09-20 |
Netris Pharma |
Anti-netrin-1-antikörper zur behandlung von leberentzündung
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
EP4249509A1
(de)
|
2022-03-22 |
2023-09-27 |
Netris Pharma |
Anti-netrin-1-antikörper gegen arthritis-assoziierte schmerzen
|
WO2023186968A1
(en)
|
2022-03-29 |
2023-10-05 |
Netris Pharma |
Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
|
US20230355792A1
(en)
|
2022-04-07 |
2023-11-09 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index
|
WO2023201201A1
(en)
|
2022-04-10 |
2023-10-19 |
Immunomic Therapeutics, Inc. |
Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023235415A1
(en)
|
2022-06-01 |
2023-12-07 |
Genentech, Inc. |
Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
WO2023240124A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Pseudotyped viral particles for targeting tcr-expressing cells
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024015953A1
(en)
|
2022-07-15 |
2024-01-18 |
Danisco Us Inc. |
Methods for producing monoclonal antibodies
|
WO2024039672A2
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against msln and methods of use thereof
|
WO2024039670A1
(en)
|
2022-08-15 |
2024-02-22 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cldn4 and methods of use thereof
|
WO2024038165A1
(en)
|
2022-08-18 |
2024-02-22 |
Immunocore Ltd |
T cell receptor fusion proteins specific for mage a4
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|